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                                                ABSTRACT 
AIM: 
        The clinical outcome of breast carcinoma varies in every individual due to 
its molecular heterogeneity. Nowadays there is a rising interest whether the 
associated DCIS in invasive ductal carcinoma of breast affects the prognosis 
and overall survival of the patient. Only a very few studies has assessed the 
expression of molecular markers between IDC-DCIS and pure IDC(IDC 
without  DCIS). So the present study was undertaken to study the expression of 
HER2/neu in invasive ductal carcinoma of breast associated with and without 
DCIS and also to find the correlation with other clinico-pathological variables 
with such expression. 
MATERIALS AND METHODS: 
         Two groups were categorized based on the presence or absence of in situ 
component in invasive ductal carcinoma of breast. A total of 50 mastectomy 
specimens were studied for the expression of HER2/neu by IHC , which 
includes 25 cases of invasive ductal carcinoma associated with DCIS (IDC-
DCIS) and 25 cases of invasive ductal carcinoma without DCIS (IDC). 
RESULTS: 
      There is no statistical difference in HER2/neu expression between IDC-
DCIS and pure IDC (IDC without DCIS) .The expression of Ki 67 was 
significantly higher (p value 0.022) in IDC without DCIS (60%) than IDC-
DCIS ( 28%).The expression of HER2/neu is associated with large tumor size, 
positive lymph node status and ER status in IDC without DCIS. Ki 67 which is 
considered a predictor of chemotherapy is correlated with HER2/neu expression 
in both the groups but significantly higher in pure IDC (without DCIS). 
CONCLUSION: 
         IDC associated with DCIS (IDC-DCIS) shows a less malignant behavior 
compared to IDC without DCIS. Since molecular markers play an important 
role in tumor carcinogenesis and progression further studies to be done in large 
scale which might help in identifying the subgroup for targeted therapy. 
Key words: Breast carcinoma, heterogeneity, carcinogenesis, HER2/neu, Ki 67. 
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INTRODUCTION 
Breast carcinoma is the most common malignant tumor among 
women .It constitutes 25% of all the cancers in women worldwide. 
1
The 
incidence of breast carcinoma has been rising due to increased 
mammographic screening and change in lifestyle .
2 
The clinical outcome of breast carcinoma varies with every 
individual due to the heterogeneous nature of the tumor .Increased use of 
mammography has led to the early detection of in situ carcinoma which 
represents 20-45% of all newly detected mammographic breast 
lesions.
3
Many studies showed about 50% of untreated DCIS progresses to 
invasive breast cancer. The duration required for the progression of in situ 
components to invasive cancer and the factors predicting such 
progression is largely unknown.
4 
In tumors with both invasive and   in situ components (IDC-DCIS), 
it is believed that the invasive cancer develops from the in situ 
component. In tumors without DCIS component, the invasive ductal 
carcinoma (IDC) is presumed to be arising directly from atypical ductal 
hyperplasia (ADH). It is also debated whether the pure IDC (IDC without 
DCIS) is distinct type from IDC associated with DCIS (IDC-DCIS). 
(5-7)
 
 
Recent studies have tried assessing the effect of presence of in situ 
carcinoma in invasive ductal carcinoma (IDC-DCIS) on the prognosis 
and overall survival of the patients. Studies done by Wong et al
6
 showed 
2 
 
that the presence of in situ component is associated with a low aggressive 
potential. Chagpar  et al
8
 concluded that the presence of in situ 
component is associated with increased disease free survival and overall 
survival. However presence of in situ component is yet to be proven as 
independent predictor of the outcome. 
 
Several molecular markers have been implicated in the 
development and prognosis of the breast cancer including hormone 
receptors (ER/ PR), HER2/neu, p53,Ki 67 etc. In addition to predict the 
prognosis, these markers are also used for target directed therapy and to 
assess the response to treatment. The effect of these markers in the IDC-
DCIS is yet to be evaluated, which might have an effect on the 
therapeutic approach to breast carcinoma.   
 
Only a very few studied the expression of HER2/neu and the 
hormone receptors (ER/PR) between the two groups (IDC and IDC-
DCIS), however the results are not consistent. 
 
Hence the present study was undertaken to evaluate the expression 
of HER2/neu in Invasive ductal carcinoma associated with DCIS (IDC-
DCIS) and invasive ductal carcinoma without DCIS (IDC) and to assess 
the correlation of other clinical and prognostic factors associated with 
such expression.
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AIMS AND OBJECTIVES 
1. To evaluate the expression of HER2/neu in Invasive ductal carcinoma 
associated with and without DCIS.  
2. To correlate the expression of HER2/neu with other prognostic factors 
a. Clinical variables (age, menopausal status) 
b. Pathological variables (tumor size, tumor grade, tumor necrosis, 
nipple invasion, lymphovascular invasion, lymph node status, ER , 
PR status and proliferation index )  
3. To determine whether the association of HER2/neu with other 
prognostic factors  differ between IDC with and without DCIS. 
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REVIEW OF LITERATURE 
History:     
Breast cancer was first noted by ancient Egyptians more than 3500 
years ago. They described it as bulging tumors in breast which has no 
cure .The descriptions of Edwin Smith and George Ebers Papyrus about 
breast tumors were consistent with the present descriptions of breast 
cancer. In 460 BC Hippocrates described breast cancer as a humoral 
disease. He also named cancer as karkinos which is a Greek word for 
crab. It was named so because the tumor seemed to have tentacles like 
legs of crab.
9
 
In 1757 Henri Le Dran suggested along with surgical removal of 
the tumor, removal of infected lymph nodes in arm pits will help to cure 
breast cancer. Claude Nicolas Le Cat also argued that breast cancer was 
only cured by surgical therapy.
10
 
By 19
th
 century William Halstead introduced radical breast surgery 
for breast cancer. In the year of 1976 Fisher noticed that breast 
conserving surgery followed by chemotherapy or radiotherapy is as 
effective as radical mastectomy. By 1995 there was a development in the 
hormonal therapies for breast cancer.
9 
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ANATOMY OF BREAST 
The breast is a modified apocrine sweat gland. It forms an 
important accessory organ of female reproductive system. 
Embryology                                  
The  mammary  glands  develops  from  the  ectodermal  mammary  
ridges  at  the  fifth  week  of  fetal  development. They  extend  on  the  
ventral  surface  of   the  fetus  from  the  axillary  to  inguinal  region  
bilaterally.  Around  seventh  week  in utero  major  part  of  mammary  
ridge  disappear . 
A small  portion  of  mammary ridge  persist  in the  fourth  or  fifth  
intercostals   space  called  the  primary  mammary  buds . Primary  buds  
of  ectoderm  starts  penetrating   downward  into  the  underlying 
mesoderm .By  12th week  of  gestation ,the  primary  mammary  buds  
develop into  secondary  buds  which  will  eventually  form  the  
mammary  lobules.  
In  fifth month  in  utero, the  ectodermal  penetration   produce   15 
–20   radial  branching ingrowths  into  the  developing  breast. Small  
lumina  will  develop within  the mammary  buds  which  forms  the  
lactiferous  ducts  and  their  branches . The lactiferous  ducts  converge  
to  open  into  a  shallow  mammary  pit ,  which  then transforms  into  
nipple  during  infancy.
11
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Anatomy 
 
The breast is covered by skin and subcutaneous tissue and it lies on 
the pectoral muscle separated by a fascia. It extends from the 2
nd 
to 6
th   
 
rib vertically and from the lateral border of sternum to the mid axillary 
line horizontally. A small extension called axillary tail of spence extends 
laterally towards the axilla. 
The nipple lies at the level of 4
th 
intercostal space. Nipple is pierced 
by 15-20 lactiferous duct .Surrounding the nipple is a circular pigmented 
area called areola. Areola is rich in modified sebaceous glands. Fibrous 
strands extend from the dermis into the breast, which attach the skin and 
nipple to the breast called the suspensory ligaments of Cooper. 
 
Fig 1:  Anatomy of breast 
The breast parenchyma is composed of glandular tissue which is 
arranged topographically into lobes. The lobes is made up of terminal 
duct lobular unit [TDLU] and the large duct system. The TDLU  is  the 
7 
 
secretory portion of breast. It consists of lobule and terminal ductule. 
Each lobule in turn is a cluster of acini. The TDLU connects with the 
lactiferous (collecting) duct by means of sub segmental and segmental 
duct. The lactiferous duct opens in to the nipple .A fusiform dilatation 
called the lactiferous sinus is present between the lactiferous and 
segmental duct. 
(12,11 )
 
The intralobular  stroma envelopes the acini of the lobules. It 
consists of   breast-specific hormonally responsive fibroblast-like cells 
admixed with scattered lymphocytes. The stroma appears myxoid .The 
interlobular stroma is made of   dense fibrous connective tissue admixed 
with adipose tissue. 
12
 
Blood supply  
Arterial supply of breast is by, 
i. Internal thoracic artery. 
ii. Branches of the lateral thoracic, superior thoracic and 
acromiothoracic arteries. 
iii. Lateral branches of posterior intercostal arteries. 
Venous drainage of the breast follows the course of arteries 
forming an anastomotic circle in the subcutaneous tissue beneath the 
nipple-areola complex.  
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From this the veins run as, 
1. Superficial veins draining into internal thoracic vein.   
2. Deep vein draining into internal thoracic, axillary and posterior 
intercostal veins.
13
 
Nerve supply:  
Nerve supply is by anterior and lateral cutaneous branches of 4
th 
and 6
th
 intercostal nerves.
13
 
Lymphatic drainage 
1. Axillary lymph nodes: Lymphatic drainage is mainly into the anterior 
group of axillary nodes. Posterior, lateral, central and apical groups of 
nodes also receive lymphatic drainage either directly or indirectly. 
2. The internal mammary nodes which lies along internal thoracic 
vessels. 
3. Supraclavicular node, cephalic node, posterior intercostal,     
subdiaphragmatic    and   subperitoneal lymph plexus
13
 
Lymphatic vessels of breast: 
1. The  superficial  lymphatics  drains overlying  skin of  breast  except 
nipple and areola .They  pass  radially  to  the  surrounding  lymph  
nodes (axillary, internal mammary, supraclavicular  and  cephalic  
node ) 
 
 
9 
 
2. The  deep  lymphatics  drain  the  parenchyma ,nipple  and  areola  of        
breast. About 75% of lymph drains into axillary nodes, 20% into 
internal   mammary nodes and 5 % into posterior intercostal nodes.
11
 
Histology 
The keratinizing squamous epithelium of the overlying skin dips 
into the orifices of the nipple. It then changes in to a double-layered 
cuboidal epithelium .The entire ductal-lobular unit is lined by two cell 
layers: luminal epithelial cells and basally located myoepithelial cells. 
Luminal cells are either columnar or cuboidal depending on their 
function.
12
 It has been  proposed that a committed stem cell in the 
terminal duct  give rise to both luminal and myoepithelial cells.
(2,12) 
The 
entire glandular epithelial system lies on a continuous basement 
membrane. Occasional scattered endocrine cells are also found in normal 
breast.
12
 
The nipple was formed by the lactiferous duct along with the 
sebaceous unit. The epidermis of nipple and areola is similar to that of 
normal skin but shows increased melanin content in basal layer. It also 
shows occasional clear cells called Toker cells in the basal layer.       
The luminal cells in the lobules are capable of producing milk .The 
contractile myoepithelial cells assist in milk ejection during lactation and 
also produces structural support to lobules.
12
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Immunohistochemically the luminal epithelial cells were positive 
for keratin, EMA, lactalbumin, GCDFP-15. Myoepithelial cells were 
positive for S-100, Smooth Musle Actin, calponin, caldesmon(duct 
portion) and also shows nuclear reactivity for p63.
12
 
Physiology of breast  
 
Estrogen and progesterone plays a major role in the development 
of breast. During the first half of menstrual cycle the lobules are 
relatively inactive. After ovulation, under the influence of estrogen and 
increasing progesterone levels, cell proliferation increases and the 
number of acini increases per lobule. The intralobular stroma will become 
edematous. During menstruation, as the estrogen and progesterone levels  
begins to fall there will be regression of the lobules with disappearance of 
the stromal edema. 
During pregnancy the breast become completely mature and 
functional .There will be a progressive increase in number and size of the 
lobules which are separated by relatively scant stroma. After delivery the 
luminal cells start  producing  colostrum  (high in protein) .As  the 
progesterone level drops  in the next 10 days there will be milk secretion( 
higher in fat and calories).On cessation of lactation the epithelial cells 
undergo apoptosis ,the lobules regress and  become atrophic. But 
however full regression will not occur. During premenopause there will 
11 
 
be involution of the lobules. In elderly females the lobules may become 
completely atrophic.
12
 
Intraductal proliferative lesions 
Intraductal proliferative lesions originate from terminal duct 
lobular unit. They are confined within mammary duct lobular system. 
They are associated with an increased risk for the subsequent 
development of invasive carcinoma. 
The WHO working group proposed a modified ductal 
intraepithelial neeoplasia(DIN) which is as follows
14
 
Table 1: Classification of Intraductal proliferative lesion 
Traditional terminology DIN terminology 
Usual ductal hyperplasia (No DIN equivalent) 
Flat epithelial atypia DIN1A 
Atypical ductal hyperplasia DIN1B 
DCIS grade I DIN1C 
DCIS grade II DIN2 
DCIS grade III DIN3 
 
             UDH has a risk of 1.5 times to develop into invasive 
carcinoma.ADH has a risk of 4-5 fold to develop into invasive carcinoma 
and DCIS have a risk of 8-10 fold.
15   
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Usual Ductal hyperplasia
 
UDH is a benign ductal proliferative lesion. Though it is not a 
precursor lesion, long term follow up of the patients with UDH shows a 
slightly elevated risk of invasive carcinoma.
16
  
Microscopy 
It shows secondary lumens of varying size and shape. The lumens 
are often peripherally distributed and in the center the proliferating cells 
are arranged in a streaming pattern.UDH have a admixture of any of the 
two or more cell types (epithelial, myoepithelial or  metaplastic  apocrine 
cells). 
Flat epithelial atypia 
It is also termed as low grade clinging carcinoma, columnar cell 
hyperplasia and columnar cell lesion.
 
Only a very few cases have 
progressed to invasive breast cancer .Several studies showed that flat 
epithelial atypia is frequently associated with DCIS, lobular carcinoma in 
situ and tubular carcinoma.
17
 
Microscopy   
The mature epithelial cells lining the ducts are replaced by a  single 
or stratified layers of mild atypical cells .Apical snouts are usually 
seen.
18
The  affected TDLU are usually distended.  Proliferating atypical 
cells are monotonous with uniform cuboidal to columnar cells forming 3-
5 cell layers 
13 
 
Atypical ductal hyperplasia 
ADH is a neoplastic intraductal lesion with a moderately elevated 
risk of developing into invasive breast cancer.ADH was first proposed by 
Page-Dupont team 
19 
for some of the proliferative lesions which did not 
show all the features of in situ carcinoma. 
Based on this, a group organised by college of American 
Pathologists
 20 
categorised fibrocystic disease into three groups ,  
1. No or mild hyperplasia : There is no risk for subsequent invasive 
breast carcinoma. 
2. Moderate or florid hyperplasia : There is risk of 1.5-2 times that of 
general   population to develop into invasive carcinoma. 
3. Atypical ductal or lobular hyperplasia:It has a risk of 5 times that of 
general population to develop into invasive carcinoma. 
Though ADH shows cytological and architectural features similar 
to that of low grade DCIS, it also shows one or more of the following 
features, 
a) Features of Usual ductal hyperplasia    
b) Only partial involvement of TDLU. 
Architectural patterns seen in ADH will be micropapillae, fronds, 
tufts, bridges, cribriform and solid patterns. The individual cells are 
monomorphic with oval to rounded nuclei. 
                            
14 
 
DUCTAL CARCINOMA IN SITU 
Ductal carcinoma in situ is a  neoplastic  intraductal lesion with 
increased epithelial proliferation with mild to marked nuclear atypia  with 
a tendency to progress towards  invasive ductal carcinoma.
14 
DCIS  is  
believed  to  originate  from  TDLU.
12 
DCIS has a relative risk of 8-11 
times to develop into invasive ductal carcinoma . 
Extensive intraductal carcinoma:  
The tumors shows intraductal component comprising about 25 % 
of the tumor area with invasion in the surrounding breast parenchyma.
21
 
Several morphological types of DCIS exist which includes the 
following, 
1. Comedocarcinoma  
Comedocarcinoma may attain a large size and become palpable. 
About half of the cases are located in the central quadrant .Multicentricity 
has been reported in about     33 % of the cases.
22
 
Gross:  
It presents as cluster of thick walled ducts with intervening breast 
parenchyma .The ducts extrudes plugs of necrotic material when they are 
compressed. The necrotic material grossly resemble that of comedones 
and so it is named as comedocarcinoma.  
 
 
15 
 
Microscopy:  
The duct shows solid growth of large pleomorphic tumor cells with 
increased mitotic activity. The diameter of the duct is larger and they 
usually have a central necrosis .The ducts in turn are surrounded by 
concentric fibrosis with mild mononuclear cell infiltration. Coarse 
calcifications are predominant in the necrotic areas which can be 
identified by mammography. The ducts involved by comedocarcinoma 
are usually surrounded by myoepithelial cells.
 23
 
When a diagnosis of comedocarcinoma is made, two factors have 
to be determined .It includes degree of intraductal spread which can result 
in pagets disease and areas of stromal invasion. 
IHC:  
They are negative for hormone receptors. HER2/neu 
overexpression and high TP53 mutations are usually seen.
22
 
2. Solid type    
In this type  the duct lumen shows proliferation of  medium sized 
cells which are smaller and uniform than the cells of comedocarcinoma 
but larger than the cells  of lobular carcinoma.
24
 
3. Cribriform type 
On microscopy it shows proliferation of uniform epithelial cells 
forming   microlumens bridging most of the duct lumen. It can be seen in 
all levels of main duct system. The microlumina may contain secretion, 
16 
 
punctate calcifications and small numbers of degenerated cells. 
Azzopardi designated that cribriform type is often associated with 
trabecular bars and roman bridges.
25 
Trabecular bars: They are rigid row of cells with the long axis of 
the nucleus are perpendicular to the long axis of the bar. 
Roman bridges: They are curvilinear trabecular bars which 
connects the two portions of epithelial lining. 
4. Papillary type   
It comprises only a small percentage of breast carcinoma. Within 
the ducts  the neoplastic epithelium  shows papillary projections 
supported by fibrovascular stroma.
12 
Micropapillary Variant  
The ducts are lined by neoplastic cells giving rise to papillary 
fronds that protrudes into the duct lumen. The papillae lack a 
fibrovascular core .The lining cells may vary from cytologically 
homogenous to highly pleomorphic . 
5. Clinging type    
           This lesion shows duct lined by  one or two layers of malignant 
cells  with a large empty lumen. It may present as high grade or low grade 
lesions. 
(12,26)
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6. Cystic hypersecretory type 
This lesion shows cystic formations which are induced by the 
abundant secretory material inside the duct.
12
  
OTHER VARIANTS: 
Ø DCIS with signet ring cells 
Ø DCIS with multinucleated Giant cells 
Ø DCIS with apocrine cytology 
Ø Clear cell DCIS 
Ø DCIS with squamous features 
Ø Neuroendocrine DCIS 
Ø Spindle cell DCIS 
Ø Small cell DCIS 
Grading of DCIS:
 
Grade of intraductal carcinoma has been used to predict the risk of 
invasive carcinoma after breast conservation therapy.
26 
There is no 
universally accepted grading system for DCIS.
14
Grading is based on 
architecture, nuclear grade, lesion size, cell polarity and presence or 
absence of necrosis. Atleast 6 classifications have been proposed and 
most classifications gave importance to the architecture, nuclear grade 
and necrosis.
27 
Silverstein et al proposed a classification based on nuclear 
grade.
28
 Presence or absence of necrosis is taken as a part of prognostic 
index. 
18 
 
There is a significant correlation between the grade of intraductal 
carcinoma and its corresponding invasive component. The risk of 
developing invasive carcinoma is higher for comedocarcinoma and lower 
for other insitu types.
(29,30)
 
DCIS is generally graded as high, intermediate and low 
grade.
(12,14,24)
A case is classified on the basis of the highest grade 
present.
31
 
The Van Nuys Prognostic Index (VNPI) 
In addition to the following histological groups margin status and 
tumor size is also included in VNPI. A significant correlation was found 
between VNPI and risk of recurrence on follow up study.
32
 
 Group 1:   Non-high nuclear grade without necrosis 
 Group 2:  Non-high nuclear grade with necrosis 
 Group 3:  High nuclear grade with or without necrosis   
Low grade DCIS  
Low grade DCIS is composed of  monomorphic cells with uniform 
sized nucleus showing diffuse finely dispersed chromatin pattern, 
occasional nucleoli and mitosis. Necrosis will be absent in low grade 
DCIS. 
Intermediate grade DCIS
 
Intermediate grade DCIS is composed of cells cytologically similar 
to that of  low grade DCIS  but some  of the ducts may show  intraluminal 
19 
 
necrosis. The nuclei may be of intermediate grade with coarse chromatin 
and occasional nucleoli. Intermediate grade can be used when the ducts 
show, 
a) Cribriform, solid or papillary pattern with necrosis. But it should 
not show nuclear anaplasia like comedocarcinoma . 
b)  The above mentioned patterns shows high grade nucleus in the 
absence of necrosis.       
High grade DCIS 
High grade DCIS is composed of atypical cells usually with central 
necrosis. The nucleus will be poorly polarized and markedly pleomorphic 
with coarse clumped chromatin .The nucleoli will be prominent .Mitotic 
figures will be conspicuous. The presence of central comedonecrosis is 
not mandatory to be graded under high grade DCIS. Even a single layer 
of highly anaplastic cells lining the ducts can also be categorised as high 
grade DCIS.
14
 High grade DCIS can be termed for  
a) Ducts showing comedocarcinoma type DCIS. 
b) Other types of DCIS showing  high grade nuclear features  with or 
without necrosis.
(12,14,26)
 
Immunohistochemistry of ductal carcinoma in situ
 
DCIS in contrast to lobular carcinoma in situ shows E-Cadherin 
expression.
33
High grade DCIS also shows P-cadherin expression. 
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1. Hormone receptors 
Studies done by Bur et al. in 1992 showed that 80% of the 
intraductal carcinomas are estrogen-receptor positive. Estrogen positivity 
is seen in 91 % of noncomedo lesions compared to that of 57% comedo 
lesions. 
34 
2. HER2/neu overexpression 
Immunoreactivity for the HER2-neu  oncogene  is seen in 42% to 
61% of  in situ carcinomas.
35
 Studies done by Ho et al. found that  
HER2/neu  amplification was higher  in comedocarcinoma (69%)  
compared to that noncomedo  type intraductal carcinomas(18%).
36 
Studies done by Van de vijver et al
35
  and Collins et al
37
 showed that 
comedocarcinoma showed HER2/neu amplification in 85% to 100% of  
cases whereas micropapillary, cribriform patten of intraductal  
carcinomas does not show HER2/neu overexpression. 
CARCINOMA BREAST 
Breast cancer is the most common  malignant cancer among 
women.
1
 The incidence has increased nowadays .This is due to increasing  
awareness  of the people and use of diagnostic  modalities like 
mammography ,fine needle aspiration and core biopsy. But the mortality 
has decreased due to early screening, which detects the tumor at an early 
curable stage and also by means of better effective treatment modalities.
2 
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Risk factors
 
Several risk factors have been established for the development of 
breast carcinoma. The common denominator for most of the factors will 
be strong and prolonged estrogen stimulation in a genetically susceptible 
background.
14 
1. Country of birth
 
The incidence is high in northern Europe and North America (91.4 
new cases per 100 000 women/year), intermediate in southern European 
and low in most Asian and African countries. In the United States due to 
increased mammographic screening   there has been a increase in the 
detection of breast carcinoma. Due to earlier diagnosis and improved 
therapy the mortality has begun to fall in some regions like North 
America, Western Europe, and Australia.
38 
Nowadays the incidence of 
breast carcinoma has been increased in less developed countries owing to 
gradual change of lifestyle of women.
12 
2. Age 
Majority of the breast cancers are detected during the reproductive 
age group.
12 
3. Family history 
The risk is 2-3 times higher than general population if the first 
degree relative of the women had breast cancer .
39 
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4. Menstrual history 
Early menarche and late menopause is associated with increased 
risk of carcinoma.
40 
5. Reproductive history  
There will be a increased risk in case of nulliparity and late age at 
first child birth. It has been documented that there is a reduced risk of 
breast carcinoma in premenopausal women who have lactated.
41 
6. Exogenous estrogens 
Recent studies showed that there is an increased risk of breast 
carcinoma in women under hormone replacement therapy than women 
using estrogen alone.
42 
7. Ionising radiation 
 An increased risk of  breast cancer has been documented on 
exposure to ionizing radiation particularly when the exposure is at the 
time of breast development.
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8. Precancerous lesion 
Complex fibroadenoma, florid hyperplasia without atypia, solitary 
papilloma without atypical hyperplasia, sclerosing adenosis are associated 
with a risk of 1.5-2 times than that of general population . Atypical ductal 
hyperplasia and atypical lobular hyperplasia are associated with a risk of 
4.0-5.0  than that of general population.
16 
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9. Genetic predisposition                                                                                           
 
 About 5-10 % of breast cancers are familial.
12
 In various studies it 
has been reported that the risk of developing breast carcinoma due to 
BRCA1 mutation will be 56% to 90% .Women carrying BRCA2 
mutation have a risk of 37% to 84% .BRCA1 mutation may account for 
about 45% of cases of hereditary breast carcinoma and they are usually of 
poorly differentiated type with high proliferative rate.
14 
10. Diet  
       Western diet (High caloric diet rich in proteins and animal fat), 
obesity, increased  alcohol consumption ,sedentary lifestyle are associated 
with increased risk of breast carcinoma.
14
 
Clinical presentation 
            The most common symptom will be breast lump (60-70%)  
followed by pain(14-18%) .Nipple discharge (7-9%) is the least common 
presenting symptom. With the introduction of mammographic screening 
there is an increased detection of asymptomatic cases. About 40-50% of 
cases present with breast lump in the upper outer quadrant .Following that 
they present in decreasing order of frequency from central, upper inner, 
lower outer to lower inner quadrant.
14 
Breast mass should be evaluated by triple assessment which 
includes clinical examination, imaging studies(mammography 
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,ultrasound) and tissue sampling either by fine needle aspiration cytology 
or needle core biopsy.
(12,14 ) 
INVASIVE DUCTAL CARCINOMA 
Invasive ductal carcinoma are tumors in which stromal invasion is 
detectable .Regardless of the presence of in situ component and the 
relative proportion of  in situ and invasive component they are included 
under invasive carcinoma. 
12
 
Invasive carcinomas can be classified into two major categories- 
ductal and lobular type. Invasive ductal carcinoma comprises 75-85% of 
mammary carcinoma .Invasive ductal carcinoma, not otherwise specified 
comprises majority of duct carcinoma .Other  relatively infrequent forms 
of  infiltrating ductal  carcinoma  include tubular, medullary, metaplastic, 
colloid carcinoma etc.,
26
   
CYTOARCHITECTURAL TYPES 
1. INVASIVE DUCTAL CARCINOMA,NOS TYPE 
IDC, NOS type comprises 75 % of all the cases of breast 
carcinoma. It represents the prototype of all breast carcinomas.
44 
Gross:  
The tumor is usually a ill circumscribed  firm tumor.It shows a 
yellowish gray cut surface.The trabeculae radiates through the 
surrounding parenchyma  in to the adjacent fat with a crab like or stellate 
configuration. In case of larger tumors areas of necrosis, hemorrhage and 
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cystic degeneration may be present. In older days the term scirrhous 
carcinoma has been used for tumors with hard consistency. The hard 
consistency is due to presence of large amounts of stroma .  
Microscopy:  
The tumor shows various growth pattern like diffuse sheets, well 
defined nests, cords, trabeculae and also as individual cells. Glandular 
differentiation may be well developed to barely detectable. The individual 
tumor cells are usually large and pleomorphic compared to that of 
classical invasive lobular carcinoma. The tumor shows prominent nuclei 
and nucleoli and increased mitotic figures. About 60% of the cases shows 
areas of necrosis. The  amount of stroma varies from scant to abundant 
desmoplastic stroma. Elastic tissue are present in about 90% of cases. The 
presence of chalky streaks on gross examination is due to the presence of 
elastosis involving the vessel and duct walls .About 60% of the cases 
show calcification. The interphase between the tumor and stroma shows 
mononuclear cell inflammatory infiltrates.
12
 
Studies done by Fisher et al. showed that lymphatic, blood vessel 
and perineural invasion was found in 33%,5% and 28% of the cases.
45 
IHC:  
The tumor cells are positive for low molecular weight keratin(8,18 
and 19) and EMA. Other sensitive breast related markers are 
mammoglobin and GCDFP 15.The basement membrane components 
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collagen 4 and laminin   shows a discontinuous linear pattern or it may be 
totally absent.
(12,14) 
2. INVASIVE CRIBRIFORM CARCINOMA 
Invasive cribriform carcinoma is a rare form of breast malignancy. 
Microscopy:   
The tumor shows a cribriform appearance similar to that of  its  
intraductal counterpart but in addition it shows stromal invasion. 
Cribriform pattern is often seen in association with tubular formations. 
Page et al proposed that the relative proportion of the two elements 
determine the term  to be  used.
46 
Prognosis: The tumor has a excellent prognosis. 
3. TUBULAR CARCINOMA 
Pure tubular carcinoma comprises less than 2% of invasive breast 
cancer. But in mammographic screening 9-19 % of cases can be detected 
.It is easily detectable due to its spiculate nature and cellular stroma. 
Gross:  
The gross feature of tubular carcinoma is similar to that IDC, NOS 
type with  poorly circumscribed margins and hard consistency. But the 
size of the tumor is usually small with  a mean diameter of 1 cm. 
Microscopy:  
The tumor shows haphazard arrangement of glands without any 
organoid configuration. The characteristic feature of tubular carcinoma is 
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irregular and angulated contour of the glands .The lining cells show 
apocrine type snouts in the apical cytoplasm. They lack myoepithelial 
cells and basement membrane. The lumina of the glands are open and 
filled with basophilic secretion. It shows a cellular desmoplastic reaction. 
The tumor is cellular with fat invasion in the periphery. Because of the 
well differentiated nature of the glands, scant pleomorphism and absence 
of necrosis it simulates benign conditions like microglandular  adenosis ,  
sclerosing adenosis and radial scar .
(12,24) 
DCIS can be seen in majority of the cases. The in situ component 
is usually of  low grade  showing cribriform or papillary pattern.
 
Prognosis:
 
Tubular pattern can be seen associated with invasive ductal 
carcinoma, NOS type  or sometimes with invasive lobular carcinoma. In 
this instances, the term tubular NOS and tubular mixed can be employed. 
When the tubular pattern is more than 75 % ,the tumor shows better 
prognosis than ductal carcinoma NOS type. The term tubular carcinoma 
can be best employed for tumors in which tubular pattern is present for 
atleast 90 % of the tumor. These tumors are  associated with favorable 
prognosis
 
4. MUCINOUS CARCINOMA
 
Mucinous carcinoma was classified under mucin producing 
carcinoma .Other mucin producing carcinomas are mucinous 
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cystadenocarcinoma, columnar cell mucinous carcinoma and signet ring 
cell carcinoma.
14 
The tumor usually occurs in postmenopausal women. It is also 
called as mucoid,  gelatinous or colloid carcinoma.
 
Gross: 
The tumor is well circumscribed .Cut surface of the tumor shows a 
characteristic glistening and gelatinous appearance. 
Microscopy: 
The tumor cells are arranged usually in small clusters floating in a 
mucinous pool which are surrounded by bands of fibrous septa. The 
tumor cells show little pleomorphism. Mitotic rate is usually low. The 
mucin is usually extracellular .The mucin may be acid or neutral type. 
The  in situ component is usually difficult to recognize. 
Histochemically the mucins are o-acylated forms of sialomucin. 
Immuohistochemically there is strong MUC2 positivity in cytoplasm. 
Estrogen and progesterone receptors are always positive whereas HER2/ 
neu will be negative.
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Few studies suggest that mucinous carcinoma can be classified as 
A and B based on the endocrine differentiation. Type A tumors shows 
tumor cells arranged as  trabeculae with minimal intracytoplasmic mucin. 
The cells do not show argyrophilia. Type Btumors shows sheets of tumor 
cells with abundant intracytoplasmic mucin.  Argyrophilia can be 
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demonstrated in the tumor cells. Nodal metastasis is very low which 
accounts for 2-4% of node metastasis.
(12,26)
 
IHC:  
They are positive for estrogen and progesterone receptors. They 
usually do not show HER2/neu overexpression or p53 accumulation. 
5. MEDULLARY CARCINOMA 
The tumor is most common in patients under 50 years of age. The 
tumor is common among carriers of BRCA1 mutation. 
Gross:  
The tumor is well circumscribed, solid and homogenous. 
Microscopy:  
         The tumor grows in a diffuse pattern with minimal or absent 
glandular differentiation. The individual tumor cells are large 
,pleomorphic with large nuclei and prominent nucleoli. The cell borders 
are indistinct which gives the tumor a syncytial arrangement. Spindle cell 
metaplasia, bizarre tumor giant cells and extensive necrosis may occur. 
The tumor shows prominent lymphoplasmacytic infiltrate at the periphery 
of the tumor which is an characteristic feature of medullary carcinoma. 
The infiltrate was thought  due to the reaction of host tissues to the 
neoplasm. They are usually peripheral T cell type. 
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IHC: 
They are positive for CK7, p53.They are negative for hormone 
receptors (ER,PR),HER2/neu and comes under Triple negative 
phenotype. The tumor expresses HLA-DR antigen which could be the 
possible reason for the prominent lymphoplasmacytic infiltrate. Though 
axillary lymph node involvement are common, only low axillary group of 
lymph nodes will be usually  involved. The prognosis will be better than 
IDC,NOS type.
(12,26)
 
Atypical medullary carcinoma: 
The tumor shows same growth pattern features  as that of typical 
medullay carcinoma but has no more than two classic microscopic 
features. 
The tumor shows  
a. Syncytial growth comprising  > 75% of the tumor 
b. Atypical features 
c. Focal tumor infiltration at the margins 
d. Uniform nuclei and rare mitosis 
e. Mild to absent lymphoplasmocytic infiltration at the margins and 
focal tubule formation seen.
 48
  
6. INVASIVE PAPILLARY CARCINOMA  
The tumor is rare and occurs more frequently in the 
postmenopausal women. Most commonly papillary carcinomas present as 
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in situ lesions. The invasive component can be papillary or it may show 
features of IDC, NOS type. As the presence  of invasion in these tumors 
are not clearcut, it should be applied for cases with well differentiated 
true papillary structures only. When a tumor with papillary pattern is 
seen, metastatic papillary carcinoma from other sites should   also be 
excluded.
(12,26) 
The tumor may have axillary lymph node metastasis particularly in 
solid variant of papillary carcinoma. Prognosis of the tumor is better 
compared to that of invasive ductal carcinoma, NOS type.
49 
7. INVASIVE MICROPAPILLARY CARCINOMA 
Invasive miropapillary carcinoma is a distinct rare variant of 
invasive ductal carcinoma. When the micropapillary pattern is found 
throughout the tumor it is referred as pure invasive micropapillary 
carcinoma. When it is present as a part of conventional IDC it is called as 
mixed invasive micropapillary carcinoma .But the criteria to distinguish 
these two is not clear cut.  Some authors suggest atleast 50 % of the 
tumor should be micropapillary to call it as pure invasive micropapillary 
carcinoma  
Microscopy: 
The tumor is composed of clusters of cells arranged in 
micropapillary or tubular pattern. The tumor cells are found free floating 
in clear spaces. Fibrovascular core will be absent in the micropapillary 
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clusters. The clusters exhibit a “inside out” arrangement. The apical cells 
are polarized outside and this can be evidenced by MUC 1 staining. 
The nuclear grade of this tumor cells will be high. About half of 
the cases may show psammoma bodies. In situ component seen in these 
cases is usually micropapillary and sometimes show cribriform pattern. 
Lymphatic invasion was reported in more than 50 % of the cases. 
Lymph node metastasis  usually occur. The tumor have a bad prognosis. 
IHC:  
Estrogen receptor were positive in 72-75 % of cases and 45 % 
cases were positive for progesterone receptor.36 % of the cases show Her 
2-neu overexpression. 
50
       
8. APOCRINE CARCINOMA 
Apocrine carcinoma is very rare comprising 0.5 % of all breast 
carcinoma. The tumor is composed entirely or predominantly of apocrine 
type cells. The tumor cells are large with abundant eosinophilic 
cytoplasm with vesicular nucleus and prominent nucleoli. Glandular 
differentiation can be seen with apocrine snouts. Diagnosis of apocrine 
carcinoma should only be made when the architectural features are those 
of a malignant tumor. Immunohistochemically they are positive for 
GCDFP-15.Estrogen and progesterone receptors will be negative.
51 
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9. SECRETORY CARCINOMA
 
Secretory carcinoma are rare tumors and seen in children. It can 
also occurs in adults. It has a excellent Prognosis.
 
Gross: 
The tumors are usually small and well circumscribed.
 
Microscopy: 
The tumor is composed of tubuloalveolar and papillary structures. 
The lumina contain eosinophilic PAS positive, diastase resistant material. 
The malignant cells have a pale staining vacuolated cytoplasm. Nucleoli 
may be prominent. Mitosis is scanty. 
IHC:  
There is a strong immunoreactivity for S-100  and a-lactalbumin. 
10. METAPLASTIC CARCINOMA 
Metaplastic carcinoma represents tumor predominantly with cell 
type other than epithelial and glandular component. It includes many 
categories but which overlap with each other.  Metaplastic carcinoma is 
more aggressive than invasive ductal carcinoma. Metastasis is usually 
hematogenous rather than lymph node metastasis. 
Gross:  
The tumors are circumscribed, firm to hard in consistency. 
Degenerated cystic areas can be seen in cases with squamous metaplasia. 
Some of the tumors may have infiltrative borders. 
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Classification of metaplastic carcinoma 
Table 2:Classification of metaplastic carcinoma. 
Purely epithelial Mixed epithelial and mesenchymal 
Squamous  
• Large cell keratinizing, 
spindle cell,acantholytic 
• Adenocarcinoma with 
spindle cell differentiation  
• Adenosquamous, including 
mucoepidermoid 
 
• Carcinoma with chondroid 
metaplasia 
• Carcinoma with osseous 
metaplasia 
• Carcinosarcoma(specify 
components). 
 
A.Squamous cell carcinoma 
Gross: 
        The tumors are large with cystic spaces filled with keratin. 
Microscopy: 
In pure squamous cell carcinoma the central cystic cavity is lined 
by malignant squamous cells. Most cases represent squamous metaphase. 
Other two variants which can be seen will be acantholytic 
squamous cell carcinoma and adenosquamous carcinoma. Low grade 
adenosquamous carcinoma is said to have a favourable prognosis whereas 
acantholytic  squamous cell carcinoma have a aggressive behavior.
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B. Carcinosarcoma 
Microscopically the sarcoma like component can be malignant 
fibrous histiocytoma, osteosarcoma, chondrosarcoma, angiosarcoma or a 
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combination of various components. When the transition between 
sarcomatous and carcinomatous component is gradual and sharp, it is 
termed carcinosarcoma.
53 
When the transition to cartilaginous or osseous elements is direct 
without an intervening spindle cell component or osteoclastic giant cells, 
it is called  matrix producing carcinoma.  
 
Molecular studies suggest that the epithelial and sarcoma like 
components originate from same stem cell.
 
IHC: 
The sarcoma like elements acquire vimentin and other 
mesenchymal features .It is referred to as the phenotypic switch. The cells 
are occasionally positive for epithelial markers. 
SPREAD RELATED VARIANTS 
1. Inflammatory carcinoma 
The diagnosis of inflammatory carcinoma is essentially based on 
clinical criteria. Clinically the entire breast is red, warm. The skin shows 
widespread edema which resembles that of mastitis. It has been believed 
that clinical appearance is due to widespread carcinomatosis of dermal 
lymphatic vessels. Skin biopsy is usually performed to reveal dermal 
lymphatic permeation. Histopathological examination of  some of the 
cases show a undifferentiated carcinoma. 
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The prognosis is usually bad. Studies done by Charafe -Jauffret et 
al.
54
 found most inflammatory carcinoma are negative for estrogen and 
positive for MIB1,E-Cadherin and  HER2/ neu. 
PAGETS DISEASE 
Pagets disease was originally described by Sir James Paget in 
1874.It is a crusted lesion of nipple caused by underlying breast 
carcinoma. About 1-2% of  patients with mammary carcinoma show 
pagets disease. The accompanying breast carcinoma is usually a 
intraductal carcinoma.
55
It may be associated with or without stromal 
invasion. The epidermis of the nipple shows characteristic Paget's cells in 
the the keratinizing epithelium. The cells may be singly scattered in the 
superficial epidermis. They may also form clusters in the basal portions 
of the epidermis. Individual cells have a pale or clear cytoplasm and their 
nuclei have a prominent nucleoli. 
Intraductal carcinoma is usually of comedo or solid growth 
pattern.About 10 % of the cases show cribriform or papillary carcinoma 
and 40 % the cases show mixed type of in situ carcinoma. 79-100 % the 
cases are strongly positive for HER2/neu.The underlying insitu lesions 
are frequently HER2/neu positive . 
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HISTOLGICAL GRADING OF DUCTAL CARCINOMA 
Grading of breast cancer was first attempted by Greenhough in 
1925.
56
He used about 18 features and it is not popular. In 1993 
Haagensen evaluated 15 histological features which mainly includes 
growth pattern, cell morphology and the stromal reaction. 
The most popular grading system till date was proposed by Bloom 
in 1950.
57
His grading system was based on  three main features  which 
includes degree of tubule formation ,nuclear features and mitotic activity 
.He classified breast carcinoma into 2 categories –low grade and high 
grade tumors.  
In 1957 this classification was upgraded by modifications of 
Bloom and Richardson .
58
It is also based on degree of tubule formation, 
nuclear pleomorphism and mitotic activity. But in this classification score 
of 1 to 3 was given to each criteria according to mild, moderate or 
marked degrees. A total score of 3 to 9 was given as follows,                                                  
Table 3 :  Bloom And Richardson grading system 1957 
Score 3-5      Grade 1 Well differentiated tumors 
Score 6-7    Grade 2 Moderately differentiated tumors 
Score 8-9    Grade 3 Poorly differentiated tumors 
           
Elston highlighted the importance of proper tissue fixation, 
appropriate section thickness for histological grading .He used the 
grading system only for  invasive ductal carcinoma. Special types like 
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mucinous, medullary carcinoma are excluded. Elston and Ellis modified 
Bloom and Richardson grading system by quantifying the mitotic 
activity.
59
This is also referred as the Nottingham modification of Bloom 
and Richardson system. 
Table 4: Nottingham modification of Bloom-Richardson Histological 
grading system 
Criteria Score 
Tubule and gland formation 
Majority of tumor (>75%) 
Moderate degree (10-75%) 
Little or none (< 10% ) 
 
1 
2 
3 
Nuclear pleomorphism     
Small, regular, uniform    
Moderate variation in size, shape 
Marked  variation in size, shape 
 
1 
2 
3 
 
Mitotic count 
Mitotic count is also graded as 1-3.But it depends on the field 
diameter used. Mitotic figures are to be counted from the most mitotically 
active area.10 high power fields should be counted from the same area 
but need not to be contiguous. Poorly preserved area should be ignored.  
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Table 5: Scoring of mitotic count 
Field diameter0.59mm Field diameter 0.44mm score 
0-9 0-5 1 
10-19 6-10 2 
>20 >11 3 
 
Final grading score 
GRADE SUM OF POINTS 
I 3–5 
II 6–7 
III 8–9 
 
PROGNOSTIC FACTORS 
1. Age  
Women < 50 years have the best prognosis. Older patients have a 
higher rate of recurrence and distant metastasis.
 
2.  Pregnancy   
Carcinoma breast manifesting during pregnancy are generally 
aggressive with overexpression of HER2/neu and low expression of 
hormone receptors . 
3. BRCA1 status 
Studies showed that BRCA1 mutation carriers have a low survival 
rate. 
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4. Skin invasion 
Invasion of overlying skin is associated with decreased survival 
rate. 
5. Nipple invasion 
Nipple areola complex involvement vary from 0 to  58 %.
(60-62)
The 
nipples are usually involved by pagets disease, invasive ductal or lobular 
carcinoma and lymphovascular invasion. Nipple involvement by invasive 
carcinoma is mostly due to direct invasion of the tumor into the 
retroareolar region.
62
 Nipple involvement is associated with high 
incidence of axillary node metastasis.  
6. Presence or absence of invasion 
The single most important prognostic determinant of breast 
carcinoma is the presence of invasive component. In case of  tumor with 
both an invasive and in situ component ,the invasive component is 
proportional to the nodal metastasis. The in situ component is directly 
related to the incidence of multicentricity and indirectly with occult 
metastasis.
12 
7. Size of the tumor 
Tumor diameter should be measured in three planes to the nearest      
millimeter. The greatest diameter is taken as the size of the tumor. When 
the tumor size is less than 1 cm or tumor with large in situ component 
measurements should be taken using stage micrometer in histological 
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sections. The invasive component is the better predictor of the total tumor 
size than the DCIS component. 
Numerous studies showed that tumor size correlates with the 
prognosis. Multivariate analysis by Nottingham/Tenovas Primary Breast 
cancer study showed tumor size is an independent prognostic variable. In 
case of node metastasis tumor size is considered as a strongest predictor 
of tumor dissemination and relapse. 
63
  
8. Histological type 
Variants of invasive ductal carcinoma like tubular carcinoma, 
cribriform carcinoma, medullary carcinoma, papillary carcinoma, pure 
mucinous carcinoma and secretoty carcinoma have a more favorable 
prognosis than Invasive ductal carcinoma, NOS type. Signet ring cell 
carcinoma has a bad prognosis.
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9. Histological grade     
Nottingham modification of the Bloom–Richardson system is used 
to grade the tumor. It is mainly used in invasive ductal carcinoma, NOS 
type. But a few suggest it can also be employed for special types of 
invasive duct carcinoma and lobular carcinoma.
64
    
10. Tumor necrosis 
Spontaneous tumor necrosis is associated with tumors showing 
high histological grade and increased incidence of lymph node 
metastases.
65 
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11. Lymphovascular emboli
 
Invasion of tumor cells into blood and lymphatic vessels is one of 
the    critical steps for metastasis.
66
 The presence of tumor emboli within 
peritumoral endothelial lined spaces was defined as lymphovascular 
invasion (LVI ).The identification of LVI may permit the determination 
of patients at increased risk for axillary involvement and distant 
metastases.
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12. Lymph node status 
Lymph node status is a powerful prognostic factor.
68 
It should be 
based on histopathological confirmation rather than clinical examination. 
Many studies showed that patients with regional node involvement have a 
bad prognosis than those without node involvement. 
Ten year survival rate for node negative patients will be 75 % 
while compared to that only 25-30% in node positive patients. Prognosis 
is also dependent on the number and the level of regional lymph nodes. 
The prognosis will be poor if greater number of nodes is involved .
69  
 
As per pathological lymph node staging in TNM staging, patients 
are categorized based on the number of nodes showing metastasis. 
(Annexure 2) 
NSABR categorises patients under two divisions for therapeutic 
purpose. They categorized patients with 1-3 positive nodes and cases with 
4 or more positive nodes.  
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13. Hormone receptors 
Expression of ER and/or PR is generally associated with a better 
outcome. Survival and response to hormone therapy are most favorable 
among women with tumors positive for both ER and PR, intermediate for 
tumors discordant on receptor status, and least favorable for tumors 
negative for both.
70
 The interrelationship of ER, PR, and HER2/neu has 
come to have an important role in the management of breast cancer. 
HER2/neu expression is generally  inversely correlated with ER and PR 
expression.
71
 It has been showed that breast carcinoma overexpressing 
HER2/neu do not respond to tamoxifen therapy. 
14. HER2 /neu expression
 
HER2 /neu overexpression correlates with the higher tumor grade. 
It is a poor prognostic factor especially when associated with lymph node 
metastasis.
73 
It is an excellent predictor of response to the drug 
trastuzumab but a weak predictor for chemotherapy.
 
15. Cell Proliferation
 
Cell proliferation has emerged as an important parameter 
especially in node positive patients. Tumors with increased proliferation 
rate behave aggressively. The   simple  method  to  assess  proliferation  
will  be  the  mitotic  count .Nowadays  Ki 67 has been  used  to  
determine  cell  proliferation  by immunohistochemistry
74 
.Other methods 
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include flow cytometry, S phase fraction are used to assess cell 
proliferation.
 
15. Microvessel density.  
Invasive breast carcinoma with prominent vascular component in 
the surrounding stroma behaves aggressively than other tumors.
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IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) or immunocytochemistry is the 
application of immunologic principles and techniques to demonstrate 
specific antigens in cells and tissue based on the antigen antibody 
interaction and it exploit the specificity at light microscopic level.
12 
Various stages of development of Immunohistochemistry include 
peroxidase–antiperoxidase method (1970), alkaline phosphatase labeling 
method(1971), avidin biotin method (1977) and two layer dextrin 
polymer technique(1993).
 
Steps of immunohistochemistry: 
ANTIGEN RETRIEVAL:  
Antigen retrieval is done to unmask the antigen determinants of 
fixed tissue sections. This can be done by 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
3. Microwave and trypsin antigen retrieval 
4. Pressure cooker antigen retrieval 
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Proteolytic enzyme digestion:  
Enzymes like trypsin and proteinases are used to breakdown the 
formalin cross linkages and unmask the antigen determinants. But there is 
a disadvantage of antigen destruction and inadequate digestion 
Microwave antigen retrieval: 
In this formalin fixed paraffin sections are boiled in various buffers 
for rapid and uniform heating. Currently this is the most common method 
used. 
Pressure cooker antigen retrieval: 
In this method also the tissue sections are boiled in buffers to 
unmask the antigens. This method is used to retrieve large number of 
slides. 
DETECTION SYSTEMS:  
After adding specific antibodies to the antigens, the antigen 
antibody complex should be detected. This is done by direct and indirect 
methods. 
Direct method: 
The primary antibody is directly conjugated with flurochrome. 
Commonly used flurochromes are horse radish peroxidase and alkaline 
phosphatase.  
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Indirect method : 
It is a two-step method .First the labeled secondary antibody reacts 
with primary antibody which is bound to specific antigen. The use of 
peroxidase enzyme complex or avidin biotin complex further increases 
the sensitivity of immunohistochemical stains. 
HORMONE RECEPTORS 
The presence of hormone receptors (estrogen, progesterone) 
correlates with the response of the tumor to endocrine therapy and 
chemotherapy. Though estrogen and progesterone are codependent 
variables, estrogen receptor status is the powerful predictive factor in 
breast cancer management.
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ER and PR are expressed in  80 % and 60 % of the breast cancer, 
respectively.
77
 There is not much correlation between receptor positivity 
and cytoarchitectural type of breast. But however some studies suggest 
that mucinous , tubular, lobular carcinoma shows high estrogen positivity. 
Medullary,  apocrine,  metaplastic  carcinoma  are estrogen negative. 
78
 
These hormone receptors are measured semiquantitatively. There are 
various scoring systems like Quick score, H score and Allred score. 
Nowadays Allred score is the most established score.It consists of a score 
for intensity ( 0 to 3) and a score for the proportion of nuclear staining(0 
to 5).The final score is obtained by the sum of proportion score and 
intensity score which ranges from 0 to 8.
(77,79)
 (Annexure 4)Invasive 
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tumor with an Allred score of more than 2 was considered to be positive 
for hormonal receptors.
79 
Ki 67      
Ki 67 is a proliferation marker. It was first identified after 
immunization  with  hodgkin’s lymphoma. The  Ki 67 monoclonal  
antibody  reacts  with  the nuclear  non histone protein   in  all  phases  of  
cell  cycle  except  G0.
80
Many studies concluded that there is significant 
correlation between high proliferative index and other prognostic factors 
like advanced clinical stage, high grade, lymph node status, estrogen 
receptor negativity and  HER2/neu positivity.
81
 High proliferative index 
has both predictive and prognostic significance in breast carcinoma. High 
Ki 67 index is correlated with decreased overall survival and relapse free 
survival irrespective of the nodal status.
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Conversely  tumors  with  higher  proliferation  rate  have  a  better  
response  to  chemotherapy.              
Ki-67 is usually expressed as the percentage of positive cells 
among 500 tumor cells. Ki 67 shows nuclear positivity. The cells should 
be counted in 10 high power fields. Cut off value for proliferation rate is 
not clear cut. There are many inter laboratory variations. Some studies 
used 10% as cut off limit. Few studies followed mean, median or 
arbitrary values .Few authors suggest that cut off value depend on clinical 
objective. A cut-off value 0f 10 % can be used to exclude patients with 
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slow proliferating tumors from chemotherapy. So that overtreatment can 
be avoided. A cut off of 25 % can be used to identify patients sensitive to 
chemotherapy. Some studies concluded 20% cut off limit correlates well 
with prognosis.
 (81,83-85)
 In St Gallens Consensus held in 2013 most of the 
panel members suggested that threshold 0f 20% correlates  well with the 
overall survival of the patients.
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HER2/neu 
The HER2 gene was originally termed neu as it was first derived 
from rat neuro/glioblastoma cell lines.
87
 Studies done by Semba & 
colleagues
88
and Di Fiore
89
& associates showed that the primary sequence 
of HER2 was related to ERBB2 family. Followed by that Akiyama and 
co workers demonstrated that  HER2 is a 185 KD glycoprotein with 
tyrosine kinase activity. 
90
 HER2/neu (c-erbB-2) is proto oncogene which 
encodes a transmembrane glyocoprotein with tyrosine kinase activity 
belonging to the epidermal growth factor receptor family. HER2 /Neu is 
located on the chromosome 17q21 .It encodes a 185 kDa protein. 
Several studies show that about 10-34% of breast carcinomas show 
over expression of HER2/neu protein.
(91,92)
 HER2/neu acts as both 
prognostic and predictive factor. Patients with HER2/neu positivity show 
a worst prognosis by decreasing survival rate and increasing disease 
recurrence rate. Studies done by Alfred Carr et al
93
 and Amanda McCann 
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et al
94
 concluded that HER2/neu is an independent prognostic indicator 
for overall survival of patients with breast carcinoma. 
Many studies show that HER2/neu over expression is associated 
with high proliferative index, high histological grade, positive axillary 
lymph node status, p53 accumulation and lack of estrogen and 
progesterone receptors. 
Besides this HER2/neu acts as a therapeutic target as it is easily 
accessible as cell surface receptor. The drug which acts against this will 
be a human monoclonal antibody, trastuzumab which was approved in 
1998 by FDA. This drug was effective in patients who are positive for 
HER2/neu  and associated with node metastasis. It improves response 
rates, survival rate when used alone or with chemotherapy. Trastuzumab 
also reduces the disease recurrence rate by 33 %.
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HER2/neu also predicts the response to anthracycline and taxane 
based therapy whereas the effects of non-anthracyclines and non taxane 
are inferior.
96
 It was found that HER2/neu positive tumors shows relative 
resistance to endocrine therapy.
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So accurate testing of HER2/neu is essential. Various methods like 
immunohistochemistry, FISH, gene based assays like southern blot, PCR 
methods and enzyme assays can be used to to HER2/neu 
amplification.The most frequent method used to assess HER2/neu is 
immunohistochemistry. The advantages of IHC over other methods are 
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simple and cost effectiveness and result can be interpreted by light 
microscopy. 
IHC is performed in formalin fixed paraffin embedded tissue 
blocks. The results are interpreted based on the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/CAP) 
guidelines.
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Table 6: Scoring system for HER2/neu as per ASCO guidelines 
 0 
 
No staining at all or very slight partial membrane staining in less 
than 10% of tumor cells. 
1+ 
 
Faint barely perceptible membrane staining in more than    10%    
of tumor cells. Cells stained in only part of the membrane. 
2+ 
 
 Weak to moderate complete membrane staining observed in more 
than 10% of tumor cells. 
3+ 
 
 Strong complete membrane staining in more  than 30% of tumor 
cells 
Recommended  guidelines by ASCO 
1. The type of fixative that can be used is 10% neutral buffered 
formalin 
2. The ideal time of fixation should be between 6-48 hrs 
3. The most reliable antibody is rabbit monoclonal antibody,4B5                            
If the results are 2 + it is recommended to perform FISH. Recently 
ASCO/CAP 
97
 has published their recommendations for HER2/neu 
testing. 
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The result is taken as positive in case of ,  
1. 3+ staining by IHC 
2. More than 6 HER2/neu gene copies in FISH 
3. FISH ratio >2.2 
The result is taken as negative when there is 
1. 0 or 1+ positivity by IHC 
2. < 4 HER2/neu copies per nucleus by FISH 
3. FISH ratio <1.8 
MOLECULAR SUBTYPE  OF  BREAST  CARCINOMA   
In the year 2000 Perou and colleagues tried to segregate breast 
carcinoma based on their gene expression profiles into distinct subgroups. 
He used microarray to demonstrate gene expression. It was accepted with 
a hope that this will provide new approach to the biology of breast cancer. 
It was also believed that it may impact on the therapeutic approach of the 
patient.
98 
The subtypes recognized by the gene expression are luminal A, 
luminal B, HER2/neu type, basal like and normal breast like. It was 
suggested that normal breast like subtype is most propably an artifact 
rather than genuine subtype. It is due to lack or sparsity of tumor in the 
tissue samples used for microarray analysis.
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As the different subtypes show specific characteristics, they may 
benefit  from different therapeutic approach. Among the subtypes, basal 
like type shows the worst prognosis.
98 
Luminal A   
It comprises 50% of the invasive breast cancer. This is seen in 
tubular carcinoma, cribriform carcinoma, low grade invasive ductal 
carcinoma NOS type and classic lobular carcinoma. It express luminal 
cytokeratins and high expression of hormone receptors. They respond 
well to chemotherapy. Response to chemotherapy is variable. The tumor 
will have good prognosis. 
Luminal B 
It comprises 20% of invasive breast carcinoma. It corresponds to 
invasive ductal carcinoma NOS type and micropapillary carcinoma. It 
express cytokeratins and moderate to weak of hormone receptors. 
Proliferation rate is higher compared to that of luminal A type. It shows 
variable expression for chemo and endocrine therapy. 
HER 2/neu 
It comprises about 15 % of invasive breast cancer. The tumors are 
usually high grade with lymph node metastasis. They are negative for 
hormone receptors .HER2/neu amplification and high proliferation is 
seen. Patients responds to trastuzumab and anthracycline based 
chemotherapy. The patients usually have a poor prognosis. 
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Basal like 
It comprises about 15 % of invasive breast carcinoma. High grade 
IDC NOS, metaplastic and medullary carcinoma comes under this 
category. They are negative for hormone receptors and HER2/neu but 
shows a high proliferation rate. 
The tumor respond to platinum based chemotherapy but do not 
show response to endocrine therapy and trastuzumab.                                          
An effort is also made to classify the tumors based on the 
immunnohistochemical expression. The panel of markers include 
estrogen receptor(ER), progesterone receptor, HER2/neu, EGFR, 
cytokeratin 5/6 and Ki 67.
99
                
Based on the reactivity they are classified as follows, 
 Table 7: Molecular typing of breast carcinoma according to 
expression of IHC markers
 
Immunoprofile Luminal A Luminal B HER2/neu Basal-like 
ER, PR 
ER and/or 
PR+ 
ER and/or 
PR+ 
ER –, PR – ER –, PR– 
HER2 and 
others 
HER2  – 
Low Ki-67 
(<14%) 
HER2+ or 
HER2 – 
Ki-67 
=14% 
HER2+ 
HER2– 
CK5/6 
and/or 
EGFR+ 
 
  
54 
 
Drawbacks 
But the classification has some drawbacks .Relatively small 
number of cases are used do define molecular subtypes and few less 
common distinct subtypes are missed out. The basal like subtype also 
contains tumors with favorable prognosis like medullary carcinoma, 
secretory carcinoma which shows the need of a low grade basal like 
subtype.
90
Currently the clinical value of molecular classification is not 
well established.                              
                               
 
 
                           
  
55 
 
MATERIALS AND METHODS 
The present study is a two group comparative study. Cases of 
modified radical mastectomy specimens received for routine 
histopathological evaluation in the department of Pathology, Tirunelveli 
medical college from January 2013 to September 2014 were taken for this 
study . 
Two group based on the presence or absence of in situ component 
associated with the invasive ductal carcinoma is studied for the 
expression of HER2/ neu and its clinical outcome. Approval of the 
Institute Ethical Committee was obtained to conduct this research study. 
Inclusion criteria 
Invasive breast carcinoma with 
Ø Invasive ductal carcinoma with DCIS(IDC-DCIS) 
Ø Invasive ductal carcinoma without DCIS.(IDC) 
Exclusion criteria 
Ø Invasive breast cancer with the histopathological diagnosis other 
than IDC (i.e. Invasive lobular carcinoma of breast etc.) 
Ø Patients who had received neoadjuvant chemotherapy  
Brief procedure: 
Demographic profile, relevant clinical history like age, menopausal 
status, etc. were recorded for all patients from the clinical case records.     
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The  received mastectomy specimens are subjected to  fixation in 
10%  neutral buffered formalin .After adequate fixation(usually 24 hours)  
surgical grossing  was done  according to the standard protocol and a 
detailed gross description was made .Extensive sampling is done to 
search for DCIS and then tissue sections are taken and subjected to 
routine manual tissue processing and paraffin embedding. Sections of 4-5 
µ thickness were taken and routinely stained with haematoxylin and eosin 
(H & E) and mounted with DPX mountant .The slides are examined and 
the tumor was graded according to Modified Bloom and Richardson 
grading system. Other prognostic variables like tumor size, presence 
/absence of DCIS component, nipple invasion, presence/absence of 
necrosis, lymphovascular invasion, number of lymph nodes showing 
metastasis were also assessed. 
Invasive ductal carcinomas without any DCIS component (IDC) 
after extensive sampling were taken as one group. The cases with 
invasive ductal carcinoma associated with DCIS (IDC-DCIS) were taken 
as the comparative group.    
Immunohistochemistry was performed on formalin-fixed and 
paraffin embedded tissue sections using standard protocol. (Annexure 3) 
IHC for HER2/neu was performed used rabbit polyclonal antibody 
(Thermo Scientific). HER2/Neu was interpreted as per ASCO guidelines 
(Table 6). Membrane staining with 3 + and 2+ immunoreactivity were 
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HER2/neu considered positive. In both the comparative groups 
HER2/neu amplification was assessed only in the invasive component. 
Immunohistochemistry for ER and PR was performed using rabbit 
monoclonal antibody (Thermo Scientific) and Allred score was used to 
interpret ER and PR staining. A score of  ≥  3is considered positive. The 
scoring system is explained in Annexure 4. 
IHC for Ki 67 was performed using mouse monoclonal 
antibody(Thermo Scientific). Expression of Ki 67 was reported as the 
percentage of positive tumor cells. A distinct nuclear immuno reactivity 
for Ki -67 was considered positive. The Ki-67 labeling index was 
determined by observing 500 tumor cell nuclei in areas of the section 
with highest labeling frequency. A cut off point of 20 % was taken to 
separate the cases into two groups: High proliferative rate(>20%) and 
Low proliferative rate (≤ 20%)  
STATISTICAL ANALYSIS : 
Statistical analysis was performed by SPSS software Version 
17(SPSS, Chicago, IL, USA).  Pearson’s chisquare   and Fisher exact test 
were used to evaluate the statistical differences between the two groups 
and to find the relation between HER2/neu with other prognostic factors. 
P value <0.05 is considered significant. 
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OBSERVATION AND RESULTS 
The study analyzed a total of 50 modified radical mastectomy 
specimens of patients with carcinoma breast in which 25 cases were of 
invasive ductal carcinoma associated with DCIS(IDC-DCIS) and another 
25cases were of invasive ductal carcinoma without DCIS(IDC) 
1. AGE: 
Table 8 :Age  distribution of patients between IDC with and without 
DCIS 
 
AGE IN YEARS 
≤  40 41-50 51-60 61-70 71-80 
IDC-DCIS (25) 1 9 9 5 1 
IDC (25) - 11 7 6 1 
Total cases (50) 1 20 16 11 2 
Chi square test                      p value  -   0.819 
 
In the present study, age of the patients ranged from 34-80 years 
with  a median age of 54 years. Majority of the cases belonged to 41-50 
years (40%) . 
IDC-DCIS , had equal number of patients in the age group of 41-50 
years(36%) and 51-60 years(36%) with  the median age of 54 years. 
In IDC the most common age group was between 41-50 years (44 
%) with the  median age of 53 years. The difference between two groups 
in relation to age was not significant.(Table 8 & chart 1) 
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2. MENOPAUSAL STATUS: 
Table 9: Distribution of menopausal status between IDC with and 
without DCIS 
 
MENOPAUSAL STATUS 
Premenopausal Postmenopausal 
IDC-DCIS (25) 12 13 
IDC (25) 8 17 
Total cases (50) 20 30 
Chi square test p value   - 0.248 
          
In our study majority of the cases belong to postmenopausal age 
group which constitutes 60 %.In IDC-DCIS 48 % of the cases are in 
premenopausal group and 52 % in postmenopausal group. In IDC without 
DCIS 32% of cases are in premenopausal group and 68% in 
postmenopausal group. 
Among the premenopausal population 60 % of the cases belong to 
IDC-DCIS category. (Table 9 & chart 2) 
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3. TUMOR SIZE 
Table 10: Distribution of  tumor size between IDC with and without 
DCIS 
 TUMOR SIZE 
< 2 cm 2-5 cm >5 cm 
IDC-DCIS (25) 4 15 6 
IDC (25) 2 14 9 
Total cases (50) 6 29 15 
Chi square test                         P value   - 0.521 
 
In both the groups majority of the patients had a tumor size 
between 2-5 cm comprising 58% followed by 30% showing >5cm .Only 
6 cases (12%)  show tumor size below 2 cm. In IDC-DCIS  15 
cases(60%) are in the size of 2-5 cm. 16 % of the cases are in  seen in  <2 
cm and 24% are in  >5 cm of tumor size. In IDC 56% (14 cases) of the 
cases are in the size of 2-5 cm.8% of the cases showed <2 cm tumor size 
whereas 36% of the cases show > 5 cm tumor size. 
IDC-DCIS shows a small tumor size in  16 % of cases compared to 
that of 8 % in IDC alone. > 5cm tumor size is seen higher in IDC without 
DCIS. (Table 10 & chart 3) 
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4. TUMOR TYPE 
Table11 : Histological type of tumor in IDC-DCIS and IDC. 
 
HISTOLOGICAL TYPE 
IDC, 
NOS 
Medullary 
carcinoma 
Mucinous 
carcinoma 
Invasive 
papillary 
carcinoma 
others 
IDC-DCIS (25) 25 - - - - 
IDC (25) 23 1 1 1 - 
Total cases (50) 47 1 1 1 - 
 
Majority of the cases belong to invasive ductal carcinoma, NOS 
type. In IDC-DCIS all the cases belong to IDC/NOS type. In IDC without 
DCIS medullary, mucinous and invasive papillary carcinoma are present 
with one case each.(Table 11;Chart 4) 
5. Distribution of DCIS in IDC with DCIS 
5 A: DCIS types (In IDC-DCIS) 
Table 12 : Distribution of  various types of DCIS in IDC-DCIS 
DCIS pattern No of cases Percentage 
Comedocarcinoma 17 68% 
Solid  3 12% 
Cribriform  2 8% 
Micropapillary  1 4% 
Mixed 2 8% 
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The DCIS component associated with IDC was predominantly 
comedo type constituting 68 %.Among other patterns solid type 
comprised 12 %, cribriform type 8% ,mixed (all non comedo types) 8 % 
and micropapillary type 4 %.(Table 12 & Chart 5) 
5 B.DCIS GRADE 
Table 13 : Histological  grade  of DCIS in IDC-DCIS 
DCIS GRADE No of cases Percentage 
High Grade 20 80% 
Intermediate Grade - - 
Low Grade 5 20% 
Total 25 100 
 
80 % of the IDC-DCIS is associated with high grade DCIS and the 
rest 20 % of the tumors showed low grade DCIS.(Table 13 & chart 6)  
6. GRADE OF INVASIVE DUCTAL CARCINOMA 
Table 14 : Distribution of histological grade of IDC in   IDC with and 
without DCIS  
 
Grade of IDC 
Grade 1 Grade 2 Grade 
IDC-DCIS (25) 6 16 3 
IDC (25) 3 17 2 
Total cases (50) 9 33 5 
Chi square test              P value   -    0.593 
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Most of the cases i.e.66 % of the cases are showing histological 
grade 2.Grading is not done in case of medullary carcinoma,mucinous 
carcinoma and invasive papillary carcinoma.  
In IDC-DCIS 24% of the cases show grade 1, 64 %  of the cases 
showed grade 2 and 12% the cases showed grade 3. In IDC without DCIS 
12 % of the cases showed grade 1, 68% of the cases showed grade 2 and 
8 % of the cases show grade 3. (Table 14 & chart 7) 
7. NECROSIS 
Table 15:Distribution of tumor necrosis in IDC with and without 
DCIS  
 Necrosis 
Present Absent 
IDC-DCIS    (25) 4 21 
IDC               (25) 4 21 
Total cases   (50) 8 42 
 Fisher  exact test                     P value    - 1.000 
 
In our study necrosis was seen in only 16% of the cases in IDC-
DCIS. 
In both IDC with and without DCIS 16%  of the cases showed 
tumor necrosis. 
There is no statistical significance in relation to tumor necrosis 
between IDC-DCIS and IDC. (Table 15 & chart 8) 
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8. NIPPLE INVASION 
Table 16: Nipple invasion in IDC with and without DCIS 
 Nipple  invasion 
Present Absent 
IDC-DCIS    (25) 1 24 
IDC               (25) 1 24 
Total cases   (50) 2 48 
Fisher exact test P value-1.000 
         
In our study only 2 cases (4%) showed nipple invasion. In both 
IDC with and without DCIS, each one case presented with  nipple 
invasion .There is no statistical significance in relation to nipple invasion 
between IDC with and without DCIS. (Table 16 & chart 9) 
 
9. LYMPHOVASCULAR INVASION 
Table 17 : Lymphovascular invasion in IDC with and without DCIS. 
 
Lymphovascular invasion 
Present Absent 
IDC-DCIS    (25) 6 19 
IDC               (25) 8 17 
Total cases   (50) 14 36 
Chi square test    P value   -0.529 
 
In our sudy 50 cases 28% of the cases showed lymphovascular 
invasion      
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In IDC-DCIS 6 cases (24%) of the cases showed lymphovascular 
invasion. In IDC without DCIS 8 cases(32%) of the cases showed 
lymphovascular invasion. (Table 17 & chart 10) 
There is no statistical significance in relation to lymphovascular 
invasion between IDC with and without DCIS 
10. LYMPH NODE STATUS 
Table 18  : Distribution of  lymph node status  between  IDC-DCIS 
and IDC  
 Node status 
1-3 nodes 4-9 nodes >9 nodes Negative 
IDC-DCIS (25) 6 6 2 11 
IDC (25)          5 9 4 7 
Total cases (50) 11 15 6 18 
Chi square test P value    - 0.522 
 
In our  study  64%  of the total cases showed lymph node 
metastasis. 15 cases i.e. 30 % of the cases show nodal involvement in the 
range of 4-9 nodes. 
In IDC-DCIS 44% of the cases did not show nodal 
involvement.24% of the cases showed nodal involvement with 1-3 and 4-
9 nodes. Higher number of nodal involvement   i.e. >9 nodes are seen in 
only 8 % of the cases. 
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In IDC alone only 28 % of the cases did  not show node metastasis. 
Majority of the cases show 4-9 node involvement with 36 % .1-3 nodes 
are involved in 20 % of the cases.16%  of the cases showed  >9 nodes. 
(Table 18 & chart 11) 
There is no statistical significance in relation to lymph node status 
between IDC with and without DCIS 
11. Estrogen receptor status 
Table 19: Estrogen receptor status in IDC with and without DCIS 
 Estrogen receptor status 
Positive Negative 
IDC-DCIS    (25) 16 9 
IDC               (25) 13 12 
Total cases   (50) 29 21 
Chi square test                            P value  -   0.390 
 
In the present study 58% of the cases showed estrogen positivity         
In IDC-DCIS 16 cases (64 %)   showed estrogen positivity.In IDC 
without DCIS  52 %  of the cases showed estrogen receptor positivity. 
Estrogen positivity is higher in IDC-DCIS compared to IDC 
without DCIS.  There is no significant difference in relation to estrogen 
status between IDC with and without DCIS. (Table 19 & chart 12)       
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12. Progesterone receptor 
Table 20: Progesterone receptor status in IDC with and without 
DCIS 
 Progesterone  receptor status 
Positive Negative 
IDC:DCIS (25) 11 14 
IDC (25) 9 16 
Total cases (50) 20 30 
Chi square test P value-0.390 
         
In the total 50 cases 40% showed progesterone positivity.  
In the present study in IDC:DCIS  44%   of the cases showed 
progesterone positivity. In IDC without DCIS 36 %  of the cases showed 
progesterone  receptor positivity. 
Progesterone positivity is higher in IDC:DCIS compared to IDC 
without DCIS. There is no significant difference in relation to 
progesterone  status between IDC with and without DCIS.(Table 20 & 
chart 13)       
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13. HER2/neu 
Table 21: HER2/neu expression between IDC with and without DCIS  
 HER2/neu 
Positive Negative 
IDC-DCIS (25) 6 19 
IDC (25) 9 16 
Total cases (50) 15 35 
Chi Square Test P value = 0.354 
 
           In our study 15 cases i.e, 30% of the cases showed HER2/neu 
overexpression. In IDC-DCIS 6 cases (24%) showed HER2/ neu 
positivity.In IDC without DCIS 9 cases (36%) showed HER2/ neu 
positivity. Among the HER2/neu positive cases 60 % of the cases are 
seen in IDC without DCIS. Only 30% of the cases are seen in invasive 
ductal carcinoma associated with DCIS. 
There is no significant difference in relation to HER2/neu status 
between IDC with and without DCIS. (Table 21 & chart 14)       
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14.Ki 67 
Table 22 :Distribution of  Ki 67 between  IDC with and without DCIS  
 Ki 67 
Low (≤ 20) High(>20) 
IDC-DCIS (25) 18 7 
IDC (25) 10 15 
Total cases (50) 28 22 
Chi Square Test P value = 0.022    
 
In the total study group 56% of the cases showed low proliferative 
index and 44 % of the cases showed high proliferation index. 
In IDC-DCIS only 28% of the cases show high proliferative index 
however in IDC without DCIS 60% showed a higher proliferative index 
which is statistically significant.(p value- 0.022) (Table 22 & chart 15)       
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CORRELATION OF  HER2/ neu WITH OTHER PROGNOSTIC 
FACTORS BETWEEN IDC WITH AND WITHOUT DCIS 
1.Age 
Table 23: Association of   HER2/neu in relation to age 
Age  in Years 
Total Cases(50) 
HER2/neu + HER2/neu - 
≤ 40 1 - 
41-50 9 11 
51-60 4 12 
61-70 1 10 
71-80 - 2 
Pearson chi square test             P value=0.333 
 
In our study HER2/neu amplification was higher in the age group 
of 41-50 years with 45 %. In the age group of ≤ 40 years only one case is 
present which showed positivity for HER2/neu. In 51-60 years 25% of 
the cases showed HER2/neu positivity. In 61-70 years only 9% the cases 
showed HER2/neu and age(Table 23) 
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Table 24 : Association of HER2/neu in relation to age between IDC 
with and without DCIS . 
AGE IN YEARS 
IDC-DCIS(25) IDC(25) 
HER2/ 
neu + 
HER2/ 
neu  - 
HER2/ 
neu+ 
HER2/ 
neu - 
≤ 40 1 - - - 
41-50 3 6 6 5 
51-60 2 7 2 5 
61-70 - 5 1 5 
71-80 - 1 - 1 
Pearson chi square test         P 
value=0.239 
          P value=0.341 
 
In both IDC with and without DCIS higher number of positivity is 
seen in the age group of 41-50 years. (Table 24 ; Chart 16 & Chart 17)       
2. Menopausal Status 
Table 25 : Association of menopausal status with HER2/ neu 
Menopausal status 
Total  cases(50) 
HER2/neu + HER2/neu 2- 
Pre menopausal 7 13 
Post menopausal 8 22 
Pearson chi square test P value= 0.528 
 
HER2/ neu positivity was higher in the postmenopausal age group . 
Among the premenopausal group 35% of the cases showed  HER2/neu 
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positivity. Among  the postmenopausal group also 26.6% the cases 
showed HER2/neu positivity. There is no significant association between 
HER2/neu and menopausal status.( Table 25)      
Table 26 :Association of HER2/neu in relation to menopausal status 
between IDC with and without DCIS 
Menopausal 
status 
IDC-DCIS(25) IDC(25) 
HER2/ 
neu+ 
HER2/ 
neu - 
HER2/ 
neu+ 
HER2/ 
neu - 
Pre menopausal 4 8 3 5 
Post menopausal 2 11 6 11 
Pearson chi square 
test 
P value=0.293 P value=0.914 
 
In IDC-DCIS premenopausal group showed  33.3% positivity and 
15.3% positivity in post menopausal group. In IDC without DCIS 
premenopausal group showed  37.5% positivity and 35.2% positivity in 
post menopausal group. (Table 26 ; Chart 18 & chart 19)       
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3.Tumor  size 
Table 27 : Association of  HER2/ neu with tumor size 
 
 
In our study  HER2/neu  positivity is higher in > 5 cm tumors with 
16% positivity of the total cases followed by 12 % in 2-5 cm and  2 % 
with tumor size <2 cm. 
Among the tumors with <2 cm size 16 % of the cases are 
HER2/neu positive,20% of the cases showed positivity  among the 2-5cm  
tumor size and 53% of the cases showed positivity with tumor size > 
5cm. (Table 27)       
  
Tumor size 
All cases(50) 
HER2/neu+ HER2/neu - 
<2 cm 1 5 
2-5 cm 6 23 
>5 cm 8 7 
Pearson chi square test P value=0.0609 
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Table 28 : Association of HER2/neu with tumor size between IDC-
DCIS and IDC 
Tumor size 
IDC-DCIS(25) IDC(25) 
HER2/ 
neu+ 
HER2/ 
neu - 
HER2/ 
neu + 
HER2/ 
neu - 
<2 cm - 4 1 1 
2-5 cm 4 11 2 12 
>5 cm 2 4 6 3 
Pearson chisquare test P value=0.447 P value=0.034 
 
In both IDC-DCIS and pure IDC  higher rate of positivity was seen 
in > 5cm tumor size. In IDC-DCIS 33.3% of the cases show positivity for 
HER2/neu in tumor size > 5cm.In IDC without DCIS group among 
tumors with >5cm size,  66.6% of the cases show positivity . 
IDC without DCIS showed a statistically significant relation 
between the size of the tumor and HER2/neu. (Table 28 ; Chart 20 & 21)         
4. Tumor grade 
    Table 29 : Association of HER2/ neu with tumor grade 
Tumor grade 
All cases (50) 
HER2/neu + HER2/neu - 
 Grade 1 1 8 
Grade 2 10 23 
Grade 3 3 2 
Pearson chisquare test P value=  0.158 
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HER2/neu positivity was higher in grade 3 tumors with 60% 
positivity followed by 30.3 % in grade 2 tumors and 11.1% in grade1 
tumors.(Table 29) 
Table 30 : Association of HER2/neu with tumor grade between IDC-
DCIS and IDC  
Tumor grade IDC-DCIS IDC 
HER2/neu+ HER2/neu- HER2/neu+ HER2/neu- 
Grade 1 1 5 0 3 
Grade 2 3 13 7 10 
Grade 3 2 1 1 1 
Pearson chi  
square test 
P value=0.101 P value=0.359 
 
In IDC-DCIS one case showed positivity out of 3 cases with 
histological grade 3.Among grade 2 tumors  18.7 % of the cases showed 
HER2/neu positivity. 
In IDC, 2 cases presented with histological grade 3 in which one 
case showed positivity for HER2/neu. Among grade 2 tumors 41.1% of 
the cases showed HER2/neu positivity.HER2/neu positivity  is not seen 
among grade1 tumors. (Table  30 ;Chart 22 & 23)         
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5.NECROSIS 
Table 31:Association of HER2/neu with tumor necrosis . 
Necrosis 
Total  cases(50) 
HER2/neu+ HER2/neu - 
Present  2 6 
Absent  13 29 
Fisher exact test P value= 1.000 
 
Among the 8 cases with tumor necrosis only 2 cases (25%) showed 
HER2/neu positivity. There is no significant correlation between necrosis 
and HER2/neu overexpression.(Table 31) 
Table 32:Association of HER2/neu with tumor necrosis between IDC-
DCIS and IDC without DCIS 
Necrosis 
IDC-DCIS(25) IDC(25) 
HER2/neu+ HER2/neu - HER2/neu+ HER2/neu - 
Present  - 4 2 2 
Absent  6 15 7 14 
Pearson chi 
square test 
P value=0.540 P value=0.602 
 
In IDC-DCIS  HER2/neu positivity is absent among tumors with 
necrosis. Among 4 cases with necrosis 2 cases showed positivity in IDC 
without DCIS. There is no significant association between tumor necrosis 
and HER2/neu overexpression in both IDC with and without DCIS. 
(Table 32; Chart 24 & 25) 
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6. Nipple invasion  
Table 33:Association of HER2/neu with nipple invasion. 
Nipple  invasion 
Total  cases(50) 
HER2/neu+ HER2/neu - 
Present  1 1 
Absent  14 9 
Fisher exact test test P value   - 1.000 
 
Among the 2 cases with nipple invasion one case showed positivity 
for HER2/neu. There is no significant relation between nipple invasion 
and HER2/neu positivity.(Table 33) 
Table 34:Association of HER2/neu with nipple invasion in IDC with 
and without DCIS 
Nipple 
invasion 
IDC-DCIS(25) IDC(25) 
HER2/neu+ HER2/neu - HER2/neu+ HER2/neu - 
Present  - 1 1 - 
Absent  6 18 8 16 
Pearson chi 
square test 
P value – 1.000 P value-0.360 
         
In IDC-DCIS only one case presented with nipple invasion which 
did not show HER2/neu overexpression. In IDC without DCIS one case 
which presented with nipple invasion showed HER2/neu positivity. 
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        There is no significant relation between nipple invasion and 
HER2/neu positivity in both IDC with and without DCIS.(Table  34 ; 
Chart 26 & 27) 
7. Lymphovascular invasion 
Table 35 : Association of HER2/neu with lymphovascular invasion  
LVI 
Total  cases(50) 
HER2/neu+ HER2/neu - 
Present  6 8 
Absent  9 27 
Fisher exact test P value= 0.304 
 
Among 14 cases with lymphovascular invasion 6 cases (42.8%) 
showed HER2/neu positivity. There is no significant association between 
lymphovascular invasion and HER2/neu positivity.(Table 35) 
Table 36 :Association of HER2/neu with lymphovascular invasion in 
IDC with and without DCIS 
LVI 
IDC-DCIS(25) IDC(25) 
HER2/neu+ HER2/neu - HER2/neu+ HER2/neu - 
Present  2 4 4 4 
Absent  4 15 5 12 
Fisher exact 
test 
P value= 0.606 P value= 0.394 
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In IDC-DCIS 2 cases (33.3% )  showed HER2/neu positivity 
among cases with lymphovascular invasion.In IDC without DCIS 50 % 
of the cases showed HER2/neu positivity in cases with lymphovascular 
invasion. Among cases without lymphovascular invasion 29.4 % of the 
cases showed HER2/neu positivity. 
There is no significant association between lymphovascular 
invasion and HER2/neu positivity in both IDC with and without DCIS. 
(Table  36; Chart 28 & 29) 
8.Lymph Node Status 
Table 37 :Association of HER2/neu with lymph node status. 
Lymph node 
Total cases 
HER2/neu+ HER2/neu - 
Positive 13 19 
Negative 2 16 
Pearson chisquare test P value=0.028 
 
        Among the HER2/neu positive cases 13 cases i.e. 86.6 % show 
nodal metastasis. Among the node positive cases,40 % of the cases show 
HER2/neu positivity. Among the node negative cases, only 11 % of the 
cases show HER2/neu positivity.There is a significant association 
between HER2/ neu and lymph node metastasis.(Table 37) 
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Table 38 :Association of HER2/neu with lymph node status between 
IDC-DCIS and IDC        
Lymph 
node 
IDC-DCIS(25) IDC(25) 
HER2/neu+ HER2/neu - HER2/neu+ HER2/neu - 
Positive 5 9 9 10 
Negative 1 10 0 6 
Pearson chi 
square test 
P value=0.180 P value=0.0305 
 
In IDC-DCIS  35.7 % of the node positive cases showed HER2/neu 
positivity.In IDC without DCIS  47.3% of the node positive cases show 
HER2/ neu positivity which was statistically significant. (Table 38; Chart 
30 & 31) 
9. Estrogen receptor 
Table 39: Association of HER2/neu with Estrogen receptor  
Estrogen 
receptor 
Total  cases(50) 
HER2/neu+ HER2/neu - 
Positive 3 26 
Negative  12 9 
Chi square test P value <0.0001 
 
Among ER positive tumors only 10.3 % of cases showed 
HER2/neu positivity.Among ER negative tumors 63.1 % of cases showed 
HER2/neu positivity.  HER2/neu positivity is higher in cases which are 
negative for estrogen receptor.(Table 39) 
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Correlation between ER and HER2/neu was done by Kendall tau b 
test.It showed  a correlation co efficient of  - 0.504 which is statistically 
significant.( P value : < 0.0001). This shows that there is a inverse 
relation between estrogen receptor status and HER2/neu expression 
which is statistically significant. 
Table 40:Association of HER2/neu with Estrogen receptor in IDC 
with and without DCIS 
Estrogen 
receptor 
IDC-DCIS(25) IDC(25) 
HER2/neu+ HER2/neu - HER2/neu+ HER2/neu - 
Positive 2 14 1 12 
Negative  4 5 8 4 
 P value=0.142 P value=0.003 
 
In IDC-DCIS among ER positive tumors only 12.5 % of the cases 
showed HER2/neu positivity. Among ER negative tumors 44.4% of the 
cases showed HER2/neu positivity.  
In IDC without DCIS, only 7.6 % of the cases showed HER2/neu 
positivity among ER positive tumors. Among ER negative tumors 66.6% 
of the cases showed HER2/neu positivity. (Table 40;Chart 32 & 
33).Kendall tau b test showed correlation co-efficient of   -0.614 with a 
significant p value(0.003). 
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10.Progesterone receptor 
Table 41: Association of HER2/neu with progesterone receptor  
Progesterone 
Receptor 
Total  cases(50) 
HER2/neu+ HER2/neu - 
Positive 2 18 
Negative  13 17 
Pearson chisquare test P value= 0.012 
          
Among PR positive tumors 10 % of the cases showed HER2/neu 
overexpression. Among PR negative tumors 43.3% of the tumors showed 
HER2/neu overexpression. There is a signicant association between PR 
and HER2/neu overexpression. Kendall tau b test for correlation showed 
a correlation co efficient of  -0.356 with a significant p value. 
This shows there is a inverse relationship between PR and 
HER2/neu overexpression which is statistically significant.    
Table 42 :Association of HER2/neu with progesterone receptor in 
IDC with and without DCIS 
Progesterone  
receptor 
IDC/DCIS(25) IDC(25) 
HER2/neu+ HER2/neu - HER2/neu+ HER2/neu - 
Positive 1 10 1 8 
Negative  5 9 8 8 
P value              0.180           0.088 
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In IDC/DCIS among PR positive tumors only 9% of the cases are 
HER2/neu positive.Among PR negative tumors 35.7 % of the tumors are 
HER2/neu positive. 
In IDC without DCIS , among  PR positive tumors only 11% of the 
cases are HER2/neu positive.Among PR negative tumors 50% of the 
tumors are HER2/neu positive.(Table  42 ; Chart 34 & 35) 
11.ki 67 
Table 43 : Association of HER2/neu with Ki 67  
Ki 67 
Total cases(50) 
HER2/neu + HER2/neu - 
Low Ki 67 (≤20) 2 26 
High Ki 67 (>20) 13 9 
Pearson chisquare test P value  <0.0001 
         
       In our study among 28 cases with low proliferative index  only 2 
cases(7%) are positive for HER2/neu. Among  22 cases  with higher 
proliferative index 59 % of the cases shows HER2/neu overexpression. 
There is a statistical significance between ki 67 and HER2/neu 
overexpression.(Table 43)        
  
84 
 
Table 44: Association of HER2/neu with Ki 67 between IDC-DCIS 
and IDC  
Proliferation 
rate 
IDC-DCIS(25) IDC(25) 
HER2/neu + HER2/neu - HER2/neu+ HER2/neu- 
Low  (≤20) 1 17 1 9 
High  (>20) 5 2 8 7 
Pearson chi 
square test 
P value=0.0005 P value=0.027 
 
In IDC-DCIS 5 % of the cases showed HER2/neu overexpression 
in low proliferative index group and 71.4 % of the cases showed 
HER2/neu overexpression among cases with higher proliferative index.     
In IDC without DCIS 10 % of the cases showed overexpression in 
low proliferative index group and  53.3 % of the cases showed 
overexpression among cases with higher proliferative index. (Table 44; 
Chart 36 & 37)   
There is a significant association between HER2/neu and Ki67 in 
both IDC-DCIS and IDC. 
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Fig  2:Gross Photograph Of Mastectomy 
Specimen C/S Shows A Irregular Greyish 
White Mass 
 
Fig 3:Invasive Ductal Carcinoma,Nos Type 
(H & E,X 100) 
 
Fig 4: Mucinous Carcinoma Of Breast (H & E,X 
100) 
 
Fig 5 : Atypical Medullary Carcinoma Of Breast  
(H & E,X 100) 
  
Fig 6:IDC, Nos Type- Grade 1 ( H & E,X 100) 
 
Fig 7: IDC, Nos Type –Grade 2( H & E, X 100) 
 
Fig 8 : IDC, Nos –Grade 3(H & E,X 100) 
  
 
 
 
 
 
 
 
Fig 9 : Comedocarcinoma Type Type DCIS 
In IDC-DCIS (H & E,X100) 
 
Fig  10: Cribriform Type Type DCIS 
In IDC-DCIS (H &E,X100) 
 
Fig 11 : Solid Type Type DCIS 
In IDC-DCIS (H & E,X 100) 
 
Fig 12: Micropapillary Type DCIS 
In IDC-DCIS (H & E,X 100) 
 
  
  FIG 13: HER2/Neu  Positivity With Score 3+ 
(DAB, X 400) 
 
FIG 14: Strong Complete Membranous 
Staining In HER2/Neu ( DAB,X 100) 
FIG 15:Ki 67 –High Proliferative Index         
( DAB,X 100) 
 
Fig 16 : Ki 67 –Low Proliferative Index 
(DAB,X 100) 
 
 Fig 17:Estrogen Receptor Positivity In IDC, 
Nos –Score 8 (DAB, X 100) 
Fig 18: ER Positive In Mucinous Carcinoma 
Of Breast (DAB,X 100) 
 
Fig 19:ER Positive-Mucinous 
Carcinoma Of Breast (DAB, X 400) 
Fig 20 : Progesterone Receptor 
Showing Nuclear Positivity In IDC, 
Nos ( DAB, X 400) 
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DISCUSSION 
 Breast carcinoma is the most common malignant tumor in females. 
The clinical outcome of breast carcinoma varies in every individual due 
to its molecular heterogeneity. Recent days there is an rising interest 
whether the association of DCIS will affect the prognosis and overall 
survival of the patient. Only a very few studies have been conducted so 
far to assess the expression of  HER2/neu in IDC-DCIS and IDC without 
DCIS(IDC). 
This present study evaluate the expression of HER2/neu between 
invasive ductal carcinoma associated with and without DCIS and also to 
assess the correlation of HER2/neu with other prognostic factors between 
IDC-DCIS and IDC.  This study includes totally 50 cases of invasive 
ductal carcinoma of breast in which 25 cases were of IDC associated with 
DCIS (IDC-DCIS) and the other 25 cases were of invasive ductal 
carcinoma without DCIS.(IDC) 
 Table  45: Number of cases studied in various studies 
Study 
Year and  
duration 
IDC-DCIS IDC without DCIS 
B H Jo et al5 1996-1997 144 84 
H Wong et al6 2000-2008 616 543 
Mylonas et al7  1999-2002 36 130 
Rana S Aziz et al101 2008-2009 12 7 
Present study 2012-2014 25 25 
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Age:   
In the present study the median age of the total cases was 54 years. 
Median age of  IDC-DCIS is 54 years and IDC is 53 years. Median age 
was higher compared to studies of  B H Jo et al5 ,H Wong et al 6. 
Menopausal status:  
Most cases are in the postmenopausal status. In our study 
premenopausal status is higher in IDC-DCIS (48%) compared to that of 
IDC(32%). Studies by B H Jo et al5, H Wong et al6 showed a higher 
proportion of premenopausal women in IDC-DCIS. 
Tumor size:  
In our study the median tumor size is 4cm. The median size of 
present study was comparatively higher than the results of H Wong et al6 
and Chagpar et al.8 
Table  46 :Comparison of tumor size with other study 
Study IDC-DCIS  IDC 
Chagpar et al8 1.37 cm 1.44 cm 
Present study  3.5 cm 4 cm 
 
Studies by Chagpar et al8 and Dieterich et al102 showed that IDC-
DCIS had a small tumor size and a significant difference in tumor size 
between the two groups. In our present study we found a relatively small 
tumor size in IDC-DCIS compared to that of IDC.  
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Tumor type:  
In our study in IDC-DCIS all the cases are  of IDC,NOS which 
showed 24% positivity. In IDC without DCIS 9 cases showed positivity 
among 22 cases of IDC, NOS. HER2/neu positivity is not seen in cases of 
medullary, mucinous and invasive papillary carcinoma. 
DCIS type : 
In our study in IDC-DCIS 68 % of the cases show 
comedocarcinoma type DCIS. This is similar to the studies of Collins et 
al29 and Sanders et al.30 
Tumor grade:   
In our present study most patients present with histological grade 2 
with 68 % in IDC-DCIS and 76 % in IDC. There is no significant 
difference between the IDC with and without DCIS.A significant increase 
in tumor grade was observed by Mylonas et al7 and Chagpar et al.8 
Tumor necrosis :  
In the present study necrosis is seen in 16 % of the cases. Studies 
done by Rashed et al103 showed tumor necrosis in 24 % of the cases. In 
our study there is equal number of cases showing tumor necrosis in IDC 
with and without DCIS. There is no statistical significance in relation to 
tumor necrosis between IDC-DCIS and IDC. 
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Nipple invasion: 
In our study only 4% of the cases showed nipple invasion. Studies 
done by Laronga et al61 showed 6 % of cases and Wang et al62 showed 9.5 
% of cases with nipple involvement. In studies done by Verma et al60 
nipple involvement is not seen. In both IDC with and without DCIS only 
4% of the cases showed nipple invasion. 
Lymphovascular invasion: 
In our study 28 % of the cases showed lymphovascular invasion. 
Studies done by Ejlertsen et al104 showed lymphovascular invasion in 
only 15% of the cases and Brachtel et al105 showed 41% of the cases with 
lymphovascular invasion. 
In IDC-DCIS 24% of the cases showed lymphovascular invasion 
and 32% of the cases showed lymphovascular invasion in IDC without 
DCIS. This was similar to the results of Wong et al6 who showed 
lymphovascular invasion increases as the size of the invasive component 
increase. 
Table 47: Comparison of  Lymphovascular invasion  with other 
study 
Study IDC-DCIS IDC 
Wong et al7 Small IDC-Large DCIS-  27% 
Large IDC-small DCIS -57.7% 
        39.2% 
Present study                        24%          32% 
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 Lymph node status:  
In the present study 72 % of the IDC cases showed lymph node 
positivity compared to that of  56 % in IDC-DCIS. In pure IDC 
i.e.without DCIS there is a higher number of lymph node involvement 
compared to that of IDC-DCIS .This results were similar to that of  H 
Wong et al6 where there is higher number of  node involvement in pure 
IDC than that of IDC-DCIS. 
Estrogen receptor:  
In the present study 58% of the cases cases showed estrogen 
receptor positivity. Studies done by Vasudha et al106 and Azizun Nisa et 
al107 showed 48.2% and 32.7% of cases with ER positivity. A higher rate 
of positivity (73%)  is seen in the study done by Ivkovic-Kapickl et al.108 
In IDC-DCIS there is a higher rate of ER positivity with 64 % 
compared to 52 % in IDC without DCIS. This was similar to the results 
of Wong et al6 and Mylonas et al7.There is no statistical significance in 
the expression of ER between IDC with and without DCIS. 
Progesterone receptor 
 In the present study 40 % of the cases showed PR 
positivity.Studies done  by Vasudha et al106 and Wang et al62 showed 
37.9% and 66 % of the cases with PR positivity. In IDC-DCIS 44 % of 
the cases showed PR positivity and 36 % of the cases showed positivity 
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in IDC without DCIS. There is no significant difference in relation to 
progesterone  status between IDC with and without DCIS 
Table 48:Comparison of ER,PR in IDC-DCIS and IDC in other 
studies. 
STUDY 
ER +(%) PR+(%) 
IDC-DCIS IDC IDC-DCIS IDC 
Mylonas et al7 48.4 54.1 46.7 71 
Wong et al6 81.5 74.0 74.7 70.5 
Present study 64 52 44 36 
 
HER2/neu 
In the present study IDC-DCIS showed amplification in 24 % of 
cases.IDC alone showed amplification in 36 % of the cases. This result 
was concurrence to the results of  Mylonas et al7 , which showed 31 % 
positivity in IDC-DCIS and 49.6 % in IDC. He suggested that since the 
expression of HER2/neu is lower in IDC-DCIS compared to that of IDC, 
IDC-DCIS may be a precursor for the development of a more aggressive 
and malignant IDC.7 
In our study there is no statistical difference in the expression of  
HER2/ neu between the IDC-DCIS and IDC.This was similar to the study 
of Rana S Aziz et al.101 They concluded that the presence or absence of in 
situ component had no effect in the expression of HER2 /neu. 
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But in contrary H Wong et al6 showed higher HER2/neu 
amplification of  25.5% in IDC-DCIS  compared to  16.2 %  in pure IDC 
Table 49:Comparison of HER2/neu expression in IDC-DCIS and 
IDC in various studies. 
Study IDC-DCIS IDC P value significance 
Present study 24% 36% 0.354 Not significant 
Mylonas et al7 31% 49.6% P<0.05 significant 
H Wong et al6 25.5% 16.2% P<0.0005 significant 
R S Aziz et al101 - - 0.243 Not significant 
 
Ki 67:  
In the present study IDC showed a higher Ki 67 index of 60 % 
compared to that of  28 % in IDC-DCIS.Our study showed a significant 
difference  in Ki 67 expression between IDC-DCIS and IDC  with a  p 
value of 0.02. This was similar to the studies of H Wong et al6, Mylonas 
et al7   which showed   a significant difference between the two groups. 
Table 50 : Comparison of  proliferative rate with other study 
Study IDC-DCIS 
IDC 
(without DCIS) 
Mylonas et al7 49.7 % 64% 
Present study 28 % 60% 
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CORRELATION OF HER2 NEU WITH OTHER PROGNOSTIC 
FACTORS 
Many studies have correlated the expression of HER2/neu with 
other prognostic factors in breast carcinoma .In our study we correlated 
the association of  HER2/ neu with  other prognostic factors in the 50 
cases of  invasive ductal carcinoma. In addition to it we have also 
attempted to compare the correlation of HER2/neu with other prognostic 
factors between IDC-DCIS and IDC without DCIS. 
In our study HER2/neu amplification was found in 30 % of the 
cases. 
Table 51  : Comparison of HER2/neu amplification in various 
studies. 
 
Age:         
In our study HER2/neu positivity is peak in the age group of 41-50 
years.HER2/neu amplification starts declining with increasing age from 
60% in 41-50 years to 26% in 51-60 years. Studies by Azizun Nisa107 
showed HER2/neu amplification decreases with age. But however 
statistically there is no association of HER2/neu with age .Studies by 
Study HER2/neu  amplification 
Ivkovic-Kapickl et al108 20% 
Ahmed et al et al109 37% 
Azizun –Nisa et al107 37.4% 
Present study 30% 
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Khorshid et al110,Al Moundhri et al111 also showed that age is not 
associated with HER2/neu amplification.  
In our study HER2/neu positivity was more common in the age 
group of 41-50 years and positivity decreased with increasing age in both 
IDC-DCIS and IDC. 
Menopausal status: 
In the present study HER2/neu overexpression was higher in 
postmenopausal patients. But there was no significant association 
between HER2/neu overexpression and menopausal status. This  results 
were similar to that of Rana S.Aziz et al101, Khorshid et al110, Al 
Moundhri et al.111There is no difference in the association on HER2/neu 
with menopausal status between IDC-DCIS and IDC without DCIS. 
Tumor size 
In our study HER2/neu positivity increases from 16 % in tumors 
<2 cm size to 20% among tumors with 2-5cm and 53% among tumors 
with size >5cm.This was similar to the study of  Ivkovic-Kapickl et al.108  
It shows HER2/neu positivity increases with increase in size of the 
tumor. Similar to our study Bhatavdekar et al112 also found higher rate of 
HER2/neuexpression in large sized tumors.  
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Table 52:comparison of HER2/neu positivity with tumor size 
Tumor size Kapickl et al108 Present study 
<2 cm 8% 16% 
2-5 cm 30% 20% 
>5cm 50% 53% 
 
But there is no statistical significance between HER2/neu 
amplification and tumor size. Studies done by Arigar113, Prati R114, Huang 
HJ et al115 also showed that tumor size is not associated with HER2/neu 
overexpression. In contrast studies by Rana S Aziz et al101, kapicl et al108, 
Vijver et al116 showed HER2/neu overexpression is significantly 
associated with large tumor size. 
In IDC-DCIS there is no association of HER2/neu positivity with 
tumor size. In pure IDC (without DCIS) 66.6% of the cases showed 
positivity in tumor size > 5cm .IDC without DCIS showed a statistical 
significant association between HER2/neu overexpression and tumor size. 
Tumor grade: 
In our study among grade 1 tumors 10% of the tumors showed 
HER2/neu positivity, grade 2 tumors show 31% of positivity and 60% of 
the grade 3 tumors showed HER2/neu overexpression. But in the present 
study there is no significant correlation between the grade of the tumor 
and HER2/neu amplification. Al Moundhri et al104 also found similar 
results. But the results were in disagreement with the studies of Rana S 
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Aziz et al101 ,Kapickl et al108, and Hoff et al117 .They showed a positive 
correlation between the grade of the tumor and HER2/neu 
overexpression. 
There is no significant association in the expression of HER2/neu 
and tumor grade in both IDC-DCIS and IDC. 
Necrosis  
In our study 25 % of the cases with necrosis showed HER2/neu 
positivity. Among tumors without necrosis 30.9 % of   the cases showed 
HER2/neu positivity. There is no significant association between tumor 
necrosis and HER2/neu overexpression. Rashed et al103 also concluded 
that necrosis and HER2/neu overexpression is not statistically 
significant.There is no significant association of HER2neu with tumor 
necrosis between IDC-DCIS and IDC. 
Nipple invasion 
There is no significant relation between nipple invasion and 
HER2/neu positivity. This was contrary to the results of Brachtel et al105 
who showed 16% amplification in cases with nipple involvement and 
Wang et al62 who showed 18 % amplification in cases with nipple 
involvement.  
Lymphovascular invasion 
In our study 42.8 % of the cases showed HER2/neu positivity 
among tumors with lymphovascular invasion. There is no significant 
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association between lymphovascular invasion and HER2/neu 
positivity..This is similar to the results of Al-Ahwal118.In his study 29.3 % 
cases showed HER2/neu amplification in cases with lymphovascular 
invasion which is not statistically significant.  
Among cases with lymphovascular invasion there is a higher rate 
of positivity (60%) in IDC without DCIS compared to 33.3 % of in IDC-
DCIS. 
Lymph node status: 
Among the total 32 node positive cases 13 cases are HER2/neu 
positive with 40% positivity. Among the node negative cases only 11.1 % 
shows HER2/neu positivity. Among the 15 cases with HER2/neu 
amplification, 13 cases i.e, 86.6% of the cases show lymph node 
metastasis. This results are similar to the results of Slamon et al91   and 
Tiwari et al119. 
Table 53 : Association of HER2/neu with lymph node status in other 
studies. 
 
 
Study No of 
HER2/neu+ cases 
Cases with lymph 
node metastasis 
% of  
positivity 
Tiwari et al119 16 14 88% 
Present study 15 13 86.6% 
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There is a significant association between the nodal and 
involvement and HER2/neu amplification. The results are similar to that 
of Tiwari et al119 and Berger et al120 .In contrary Ivkovic-kapicl et al108 
Azizun-Nisa et al107 and Al moundhri111did not find a significant 
correlation between lymph node status and HER2/neu expression. 
There is higher rate of HER2/neu overexpression in pure IDC 
(47.3%) compared to 35.7% in IDC -DCIS in cases showing  lymph node 
metastasis. IDC without DCIS showed a significant association between 
lymph node metastasis and HER2/neu overexpression. 
Estrogen receptor status  
In our study HER2/neu positivity is higher (63.1%) in tumors 
which are negative for ER. There is inverse relationship between ER and 
HER2/neu overexpression which is statistically significant. This results 
were similar to that of Vasudha et al.106 and Ivkovic-kapickl108 .In both 
IDC-DCIS and IDC without DCIS  HER2/neu  positivity is higher in 
tumors with ER negativity but a statistically significant association is 
observed in IDC without DCIS. 
Progesterone receptor 
In our study among PR negative tumors HER2/neu positivity is 
higher with 35.7%.There is a significant inverse association between PR 
and HER2/neu overexpression which is similar to the studies of  Vasudha 
et al.106 and Ivkovic-kapickl et al108 .In both IDC with and without DCIS 
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HER2/neu positivity is higher in tumors with PR negativity but there is 
no  statistically significant relation. 
Ki 67 : 
In our present study significant correlation was found between 
HER2/neu and ki67.Among the 21 cases of high proliferative index,13 
cases i.e, 59% showed positivity for HER2/ neu overexpression.  Among 
28 cases of low proliferative rate only 2 cases i.e, 7 % showed HER2/neu 
positivity. The results were similar to that of Kilickap et al 81 and Ivkovic-
kapickl et al.108The percentage of positivity is higher in our study 
compared to the study of Ivkovic- kapickl et al.108      
Table 54 :Association of HER2/neu with Ki67 in other studies. 
Study 
% of HER2 + in Low 
proliferative cases 
% of HER2 + in high 
proliferative cases 
Kapickl etal108 0 25% 
Present study 7% 59% 
 
HER2/neu is significantly associated with Ki 67 in both IDC 
associated with and without DCIS 
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SUMMARY 
 This study includes a total 50 cases of invasive ductal carcinoma with 
25 cases of   IDC-DCIS and 25 cases of IDC without DCIS. 
 Most common age group in IDC-DCIS is 41-60 years and 41-50 years 
in IDC. 
 60 % of the cases are in postmenopausal status .Patients with 
premenopausal status are higher in IDC-DCIS compared to IDC. 
 Most common tumor size is between 2-5 cm with 58%  of the cases.  
 IDC-DCIS showed a smaller tumor size (< 2cm)   in 20% of cases  
compared to 8 % in IDC. 
 Higher rate of lymph node metastasis was seen in 72% of the cases in 
IDC compared to 56 % in IDC-DCIS. Higher number of node 
involvement (>9 nodes) is seen in 16 % of cases in IDC and 8% of 
cases in IDC-DCIS.  
 Higher proliferative rate was in 60% of cases in IDC than 28% in 
IDC-DCIS. There is a statically significance in the proliferation rate 
between IDC-DCIS and IDC. 
 HER2/neu amplification is seen in 36 % of IDC and 24% in IDC-
DCIS. No statistical significance was seen in the expression of 
HER2/neu between IDC-DCIS and IDC. 
 Only expression of Ki 67 is significant between the two groups. 
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 HER2/neu is significantly correlated with lymph node status and Ki 
67 expression in the total 50 cases .Significant inverse association was 
seen between HER2/neu and ER, PR status.  
 There is no significant correlation of HER2/neu with other prognostic 
factors like age, menopausal status, tumor size and histological grade, 
tumor necrosis , nipple invasion and lymphovascular invasion. 
 In IDC-DCIS significant association was seen between HER2/neu and 
Ki 67.No association was seen between HER2/neu and other 
prognostic features. 
 In IDC without DCIS significant association was found between 
tumor size, lymph node status, estrogen receptor (inverse association) 
and Ki 67 expression. No significant association was seen between 
HER2/neu and other prognostic factors.  
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CONCLUSION 
In our study it has been found that HER2/neu expression is not 
significantly different between IDC with (IDC-DCIS) and without 
DCIS(pure IDC). However the expression of HER2/neu was found to be 
high in the IDC group and significantly associated with the larger tumor 
size and positive lymph node status. The proliferative index (Ki 67) 
which is considered as a marker of chemotherapy response was 
significantly high in the pure IDC group. This could implicate the less 
malignant behavior of the IDC- DCIS compared to pure IDC.  
Since molecular markers play an important role in carcinogenesis 
and cancer progression, further studies at a large scale to be done to 
substantiate the finding of this study which might help in identifying the 
subgroup for targeted therapy. 
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ANNEXURE 1 
WHO   HISTOLOGICAL CLASSIFICATION OF TUMORS OF 
BREAST 
Epithelial tumors 
Invasive ductal carcinoma,not otherwise specified 
 Mixed type carcinoma 
 Pleomorphic carcinoma 
 Carcinoma with osteoclast like giant cells 
 Carcinoma with choriocarcinomatous features 
 Carcinoma with melanotic features       
Invasive lobular carcinoma 
Tubular carcinoma 
Invasive cribriform carcinoma 
Medullary carcinoma 
Mucinous carcinoma and other tumors with abundant mucin 
 Mucinous carcinoma 
 Cystadenocarcinoma and columnar cell mucinous carcinoma 
 Signet ring carcinoma 
Neuroendocrine tumors 
 Solid neuroendocrine carcinoma 
 Atypical carcinoid tumor 
 Small cell/oat cell carcinoma 
 Large cell neuroendocrine carcinoma 
Invasive papillary carcinoma  
Invasive micropapillary carcinoma 
Apocrine carcinoma 
Metaplastic carcinoma 
 Pure epithelial metaplastic carcinoma 
 Squamous cell carcinoma 
 Adeno carcinoma with spindle cell metaplasia 
 Adenosquamous carcinoma 
 Mucoepidermoid carcinoma 
 Mixed epithelial/mesenchymal metaplastic carcinoma 
Lipid rich carcinoma 
Secretory carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen rich clear cell carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Lobular neoplasia 
 Lobular carcinoma in situ 
 
Intraductal proliferative lesions 
 Usual ductal hyperplasia 
 Flat epithelial  atypia 
 Atypical ductal hyperplasia 
 Ductal carcinoma on situ 
Microinvasive carcinoma 
Intraductal papillary neoplasm 
 Central papilloma 
 Peripheral papilloma 
 Atypical  papilloma 
 Intraductal papillary carcinoma 
 Intracystic papillary carcinoma 
Benign epithelial proliferations 
Adenosis including variants 
 Sclerosing Adenosis 
 Apocrine Adenosis 
 Blunt duct Adenosis 
 Microglandular Adenosis 
 Adenomyoepithelial Adenosis 
Radial scar/complex sclerosing lesion 
  
Adenomas  
 Tubular Adenoma 
 Lactating Adenoma 
 Apocrine Adenoma 
 Pleomorphic Adenoma 
 Ductal Adenoma                    
 Myoepithelial lesions 
Myoepitheliosis 
Adenomyoepithelial adenosis 
Adenomyoepithelioma 
Malignant myoepithelioma 
Mesenchymal tumors 
Hemangioma  
Angiomatosis   
Hemangiopericytoma 
Pseudoangiomatous stromal hyperplasia 
Myofibroblastoma 
Fibromatosis  
Inflammatory myofibroblastic tumor 
Lipoma 
Angiolipoma 
Granular cell tumor 
Neurofibroma 
Schwannoma 
Angiosarcoma 
Liposarcoma 
Rhabdomyosarcoma 
Osteosarcoma 
Leiomyoma 
Leiomyosarcoma 
Fibroepithelial tumors 
Fibroadenoma 
Phyllodes tumor 
 Benign 
 Borderline  
 Malignant 
Periductal stromal sarcoma,low grade 
Mammary hamartoma 
Tumors of the nipple 
Nipple adenoma 
Syringomatous adenoma 
Pagets disease of nipple 
Malignant lymphoma   
Diffuse large B cell lymphoma 
Burkitt’s lymphoma 
Extranodal marginal zone B Cell lymphoma 
Follicular lymphoma 
Metastatic tumors 
Tumors of the male breast 
Gynaecomastia   ,  Carcinoma :invasive, insitu 
  
ANNEXURE 2 
TNM CLASSIFICATION OF BREAST CARCINOMA 
Primary tumor (T):  
TX    :   Primary tumor cannot be assessed  
T0      :   No evidence of primary tumor  
Tis      :  Carcinoma in situ; intraductal carcinoma, lobular  
carcinoma in situ, or Paget's disease of the nipple with  
no associated tumor.  
T1      :  Tumor 2.0 cm or less in greatest dimension  
    T1mic-  Microinvasion 0.1 cm or less in greatest  
dimension  
   T1a- Tumor more than 0.1 but not more than 0.5 cm  
in greatest  dimension  
 T1b-Tumor more than 0.5 cm but not more than 1.0 
cm in greatest dimension  
T1c-Tumor more than 1.0 cm but not more than 2.0 
cm in greatest dimension  
 T2      :  Tumor more than 2.0 cm but not more than 5.0 cm in  
greatest dimension 
 T3      :   Tumor more than 5.0 cm in greatest dimension 
 T4      :  Tumor of any size with direct extension to 
T4a: Extension to chest wall  
T4b: Edema (including peau d'orange) or ulceration of 
the skin of the breast or satellite skin nodules confined 
to the same breast  
T4c: Both of the above (T4a and T4b)  
T4d: Inflammatory carcinoma 
Regional lymph nodes (N):  
NX  :  Regional lymph nodes cannot be assessed (e.g.,  
previously removed)  
N0  :  No regional lymph node metastasis  
N1  :  Metastasis to movable ipsilateral axillary lymph  
node(s)  
N2  :  Metastasis to ipsilateral axillary lymph node(s) fixed  
to each other or to other structures  
N3  :  Metastasis to ipsilateral internal mammary lymph  
node(s)  
Pathologic classification (pN):  
pnx  :   Regional lymph nodes cannot be assessed (not  
removed for pathologic study or previously removed)  
pN0  :   No regional lymph node metastasis  
pN1  :   Metastasis to movable ipsilateral axillary lymph  
node(s)  
pN1a  :   Only micrometastasis (none larger than 0.2 cm)  
pN1b  :   Metastasis to lymph node(s), any larger than 0.2 cm  
pN1bi :   Metastasis in 1 to 3 lymph nodes, any more than 0.2  
cm and all less than 2.0 cm in greatest dimension  
pN1bii :  Metastasis to 4 or more lymph nodes, any more than  
0.2 cm and all less than 2.0 cm in greatest dimension  
pN1biii :  Extension of tumor beyond the capsule of a lymph  
node metastasis less than 2.0 cm in greatest dimension  
pN1biv :  Metastasis to a lymph node 2.0 cm or more in greatest  
dimension  
pN2  :  Metastasis to ipsilateral axillary lymph node(s) fixed  
to each other or to other structures  
pN3  :  Metastasis to ipsilateral internal mammary lymph  
node(s)  
Distant metastasis (M):  
MX  :  Presence of distant metastasis cannot be assessed  
M0  :  No distant metastasis  
M1  :  Distant metastasis present (includes metastasis to  
ipsilateral supraclavicular lymph nodes)  
  
TNM STAGING 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
T1 N1mi M0 
IIA T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
IIB T2 N1 M0 
T3 N0 M0 
IIIA T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
IIIB T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
 
                                                   
 
ANNEXURE 3 
PROCESSING FOR IMMUNOHISTOCHEMISTRY 
 3µm thickness sections were cut using microtome from the selected  
paraffin blocks. 
 The sections are taken in poly L-lysine coated adhesive slides.The 
slides are incubated at 60º C  for one hour.   
 The slides are subjected to 2 changes of xylene  5  minutes each for 
deparaffinization. 
 They are then transferred to absolute alcohol for 5 minutes followed 
by by 80% and 70% alcohol for 5 minutes to rehydrate the tissue 
sections. 
  Tissue sections are then placed in running tap water for 5 minutes and 
washed in distilled water 
 Antigen  retrieval was performed using pressure cooker in specific 
buffer (citrate buffer for HER2/neu and TRIS EDTA buffer for ER,PR 
and ki 67) 
 Then the sections are cooled to room temperature and the slides are 
washed with distilled water 
 Endogenous peroxidase activity is removed by incubating the tissue 
sections with enough drops of 3% peroxide block in a humidity 
chamber for 5 minutes. The sections are then washed in TRIS wash 
buffer. 
 Protein block is then added for 5 minutes followed by wash in TRIS 
wash buffer 
 Primary antibody (Her2 neu/Ki67/ER/PR) is then added over the 
tissue sections and incubated for 30 minutes . 
 The tissue sections are then washed in TRIS wash buffer. 
 Followed by that primary amplifier is added for 15 minutes to enhance 
the process of primary antibody which is then washed in TRIS  wash 
buffer 
 Secondary antibody is added and incubated for 20 minutes  and then 
washed with TRIS  wash buffer 
 DAB chromogen (1ml DAB buffer +1 drop DAB chromogen) is then 
added over the tissue and incubated for 4 minutes and then washed 
with 2 changes of distilled water. 
 Counterstaining was done with Mayer’s haematoxylin for 30 seconds 
and washed in running tap water. 
 Dehydration is done by  2 changes of   100 % alcohol. 
 Mounting is done by DPX mountant and observed under microscope. 
BUFFER PREPARATIONS 
1) Tris – EDTA Buffer: - PH- 9.0 
Tris                      -  6.05 Gms 
EDTA                   -  0.744gms 
Distilled water   -  1000ml 
2) Citrate buffer :-   p H-6.9  
Citrate  -  1.92 gms 
Distilled water - 1000 ml   
3) Tris wash buffer 
Tris               -     0.605 gm   
Sodium chloride - 8 gm 
1 N Hcl                 - 4ml 
Distilled water -  1000 ml 
PRECAUTIONS 
1. The glasswares used should be dry and clean. 
2. All the buffers used should be  prepared fresh  and the  p H should 
be adjusted according to the preferred p H. 
3. The staining procedures are never allowed to dry so they are 
performed under a humidity chamber. 
4. DAB  chromogen should be handled and disposed carefully as it is 
a carcinogen. 
5. Primary,secondary antibody, DAB chromogen,peroxidase 
block,amplifier ,everything should be stored at 4-6ºC 
While performing IHC every batch should have a positive control slide. 
 
 
 
ANNEXURE 4 
ALLRED SCORING GUIDELINES FOR ER AND PR 
Proportion score 
Proportion score  is done by calculating the  proportion of tumor 
cells with     positive nuclear staining 
0  =  no nuclear staining 
1  =  <1% nuclear staining 
2  =  1%-10% nuclear staining, 
3  =  11%-33% nuclear staining 
4  =  34%-66% nuclear staining  
5  =  67%-100% nuclear staining 
Intensity of staining 
0  =  no staining 
1  =  weak staining 
2  =  moderate staining  
3  =  strong staining 
Total score =proportion score + intensity score  ( 0 to 8) 
Interpretation:. 
  0,2   -   Negative 
≥ 3   -   Positive   
  
ANNEXURE 5 
PROFORMA 
Case number               :                 Name : 
HPE number            :           Age : 
IP number          :                Gender : 
 
CLINICAL DETAILS 
 Presenting complaints and duration 
 Family history 
 Menstrual and reproductive history 
 H/O hormone replacement therapy ,radiation exposure 
SURGICAL DETAILS 
 Type of surgery 
 Lymphnodes submitted or not 
HISTOPATHOLOGICAL DETAILS 
A.GROSS: 
1. Tumor location 
2. Tumor size ( cms) 
3. Skin / Nipple involvement – present / absent 
4. Tumor margins and consistency of the tumor. 
5. Distance of the tumor from surgical margins. 
6. Lymph nodes : present / absent. 
MICROSCOPY 
1. Tumor type 
2. Grade of the tumor 
3. Presence or absence of in situ component. If  present type and 
grade of DCIS. 
4. Lymphovascular invasion. 
5. Presence/absence of necrosis. 
6. Surgical margin status. 
7. Lymph node involvement 
IMMUNOHISTOCHEMISTRY 
1. ER, PR 
2. HER2/neu 
3. Ki 67-   < 20 % or  ≥ 20. 
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KEY TO MASTERCHART 
1.Category   :        1-IDC with DCIS (IDC-DCIS) 
                             2-IDC without DCIS(IDC) 
2.Menopausal status :  1-Premenopausal 
                                     2-Postmenopausal 
3.DCIS type   :  C- Comedocarcinoma 
                          CR-Cribriform type 
                          S- Solid type   
                          MP-Micropapillary type 
                          M – Mixed type. 
4.DCIS GRADE :  1-High grade DCIS 
                               2-Intermediate grade DCIS 
                               3-Low grade DCIS 
5. IDC histological grade:   1- Grade 1                     
                                             2-Grade 2 
                                             3-Grade 3 
6.Necrosis :             +  : Present 
                                -  :  Absent 
7.Nipple invasion:     +   :  Present        
                                NEG-  Absent 
8.Lymphovascular invasion(LVI) :      + : Present 
                                                          NEG :Absent 
 9.Lymph node status :  NEG –not involved 
                                    1      : 1-3 Nodes involved 
                                    2      : 4-9 Nodes involved 
                                    3      :  > 9 Nodes  involved    
10.Estrogen receptor status(ER)     
                                   +      :  Positive 
                                  -        :   Negative 
11.Progesterone receptor status(PR) 
                                  +       :  Positive 
                                  -        :  Negative 
12.HER2/neu  
                                 0 , 1 + : Negative 
                                 2+,3+  : Positive  
 
 
